Involvement of oral contraceptive side effects and genes in body dissatisfaction and eating dysfunction by Bird, Jessica L.
Lakehead University
Knowledge Commons,http://knowledgecommons.lakeheadu.ca
Electronic Theses and Dissertations Retrospective theses
2006
Involvement of oral contraceptive side




Downloaded from Lakehead University, KnowledgeCommons
The Involvem ent o f  i 
Running head: HORMONES, GENES AND BODY DISSATISFACTION
The Involvement o f Oral Contraceptive Side Effects and Genes 
in Body Dissatisfaction and Eating Dysfunction 
Jessica L. Bird 
Lakehead University 
MA Thesis 
Supervisor: Dr. K. Oinonen
Copyright © Jessica Bird, 2006.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1^1 Library and Archives Canada
Published Heritage 
Branch
395 Wellington Street 






395, rue Wellington 
Ottawa ON K1A 0N4 
Canada
Your file Votre référence 
ISBN: 978-0-494-21527-2 
Our file Notre référence 
ISBN: 978-0-494-21527-2
NOTICE:
The author has granted a non­
exclusive license allowing Library 
and Archives Canada to reproduce, 
publish, archive, preserve, conserve, 
communicate to the public by 
telecommunication or on the Internet, 
loan, distribute and sell theses 
worldwide, for commercial or non­
commercial purposes, in microform, 
paper, electronic and/or any other 
formats.
AVIS:
L'auteur a accordé une licence non exclusive 
permettant à la Bibliothèque et Archives 
Canada de reproduire, publier, archiver, 
sauvegarder, conserver, transmettre au public 
par télécommunication ou par l'Internet, prêter, 
distribuer et vendre des thèses partout dans 
le monde, à des fins commerciales ou autres, 
sur support microforme, papier, électronique 
et/ou autres formats.
The author retains copyright 
ownership and moral rights in 
this thesis. Neither the thesis 
nor substantial extracts from it 
may be printed or otherwise 
reproduced without the author's 
permission.
L'auteur conserve la propriété du droit d'auteur 
et des droits moraux qui protège cette thèse.
Ni la thèse ni des extraits substantiels de 
celle-ci ne doivent être imprimés ou autrement 
reproduits sans son autorisation.
In compliance with the Canadian 
Privacy Act some supporting 
forms may have been removed 
from this thesis.
Conformément à la loi canadienne 
sur la protection de la vie privée, 
quelques formulaires secondaires 
ont été enlevés de cette thèse.
While these forms may be included 
in the document page count, 
their removal does not represent 
any loss of content from the 
thesis.
Canada
Bien que ces formulaires 
aient inclus dans la pagination, 
il n'y aura aucun contenu manquant.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The Involvement of ii
Abstract
Previous research has indicated that body dissatisfaction and eating dysfunction fluctuate with 
hormone levels (Lester, Keel & Lipson, 2003). However, the impact o f  oral contraceptives 
(OCs) on these phenomena has not yet been assessed. Research has also indicated a genetic 
component to eating disorders and body image, and certain genes have been implicated, 
although none consistently (Gorwood, Kipman & Foulon, 2003). This study examined the link 
between oral contraceptive side effects and both body dissatisfaction and eating dysfunction, 
and the link between various hormonal genes and these constructs. Two-hundred-seventy-nine 
female participants completed a screening questionnaire which contained questions on OC use 
and three subscales o f  the Eating Disorder Inventory-2. O f these participants, 127 women 
provided a sample o f DNA to be analyzed. After controlling for BMI and lifetime history of 
depression, number o f  oral contraceptive mood and physical side effects significantly predicted 
both body dissatisfaction and eating dysfunction. Furthermore, mood side effects were a 
unique predictor o f both criterion variables. Examination o f the TA repeat on the estrogen 
receptor alpha gene revealed a trend such that participants homozygous for long alleles had 
higher mean eating dysfunction when compared to those homozygous for short alleles. A 
significant association was found between the estrogen receptor beta genotype and body mass 
index (BMI). Women with short/long heterozygous alleles on the CA repeat had a significantly 
higher BMI when compared to those with homozygous short alleles. The number o f  repeats on 
the serotonin transporter gene and the progesterone receptor gene were not related to eating 
disorder symptoms. These findings provide additional support for a role o f estn ' and the 
estrogen receptor genes in eating disorders symptoms and BMI.
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The Involvement o f  Oral Contraceptive Side Effects and Genes
in Body Dissatisfaction and Eating Dysfunction 
Current research on eating disorders tends to focus on psychosocial factors that 
contribute to the disorders, including personality, familial and developmental factors and 
psychiatric comorbidity (e.g., see reviews by Lilenfeld, 2004; Michel & Willard, 2004; Steiger 
& Bruce, 2004). Societal pressure on women to be thin has also been widely studied (see 
review by Fallon, 1990). Recently, however, some studies have focused on biological and 
genetic factors that might contribute to the etiology o f  disorders like anorexia nervosa and 
bulim ia nervosa (e.g., see review by  Bulik, 2004; M onteleone et ah, 2003). Gonadal hormones 
have been implicated (Klump et ah, 2006), and this line o f  research has prompted genetic 
studies focusing on estrogen and serotonin genes (e.g., Eastwood, Brown, Markovic, & Fieri, 
2002; Gorwood, 2004). Far more studies are needed to understand the complex role that both 
endogenous and exogenous hormones might play in eating disorder symptomatology. The 
present study examined body dissatisfaction and eating dysfunction, key aspects o f  eating 
disorder symptomatology, and their relationship to both the experience o f side effects produced 
by the exogenous hormones in oral contraceptives and four genes coding for important 
endogenous hormones and neurotransmitters.
Eating Disorder Symptomatology 
Poor body image has long been viewed as a major factor in maintaining eating 
disorders and has been documented as playing a role in anorexia nervosa, bulimia nervosa, and 
overeating (Allison, 1995). Poor body image is also widespread in non-clinical populations, 
especially in young women, and increasingly in girls. The Canadian Research Institute for the 
Advancement o f Women states that 60% o f high school-aged females and 80% o f university- 
aged females are dissatisfied with their bodies (Morris, 2001). Dissatisfaction often resides 
with particular body parts, including hips, thighs, and abdomen (Rosen, 1990). Dissatisfaction
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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is expressed as the belief that the body part is too fat and accompanying thoughts that the part
is ugly or disgusting. In clinical eating disorder populations it is found that patients’ self-worth
is based upon their physical attributes o f weight and shape. Patients also tend to believe that
others are judging them mainly based upon their appearance. These features o f body
dissatisfaction are fundamental in the clinical pictures o f eating disorders, but are also found to
varying degrees in non-clinical populations o f  women.
Disordered eating in patients with anorexia and bulimia nervosa involves a num ber o f 
behaviours. W eight loss is accomplished mainly through a reduction in food intake, especially 
foods perceived to be high in calories (American Psychiatric Association, 2000). Bingeing is a 
main feature o f bulimia but also occurs in the binge/purge subtype of anorexia. It involves 
consuming, in a discrete period o f  time, a quantity o f food that is much larger than what most 
people would eat in a similar period. W eight loss and compensation for binge episodes is often 
accomplished by  excessive exercise, dieting and fasting. M any individuals with anorexia or 
bulimia also engage in purging behaviours that include self-induced vomiting and the misuse 
o f laxatives or diuretics. Avoidance o f dietary fat, a behaviour observed in clinical studies o f 
anorexic and bulimic patients, was found to be the dietary feature most strongly associated 
with increased degree of eating pathology in university-aged females (Rock, Gorenflo, 
Drewnowski, & Demitrack, 1996). Thus, some degree o f eating pathology appears to be 
present in nonclinical populations o f young women.
Body dissatisfaction has been named as the strongest predictor o f  eating disorder 
symptomology in women (Tylka, 2004). Several studies have also demonstrated that body 
dissatisfaction is related to eating dysfunction and related attitudes in non-clinical populations 
o f young women (Rosen, 1990). A longitudinal study by Cooley and Toray (2001) suggests 
that eating pathology is correlated with body image. Their study followed college women for 
three years and found that changes in Bulimia and Restraint scales were significantly related to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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figure dissatisfaction. A related study by Gross and Rosen (1988) found that body
dissatisfaction was a better predictor o f bulimic eating attitudes and behaviours than self­
esteem, depression, and social anxiety combined. Therefore, it is important to examine factors 
which might contribute to body dissatisfaction in clinical and non-clinical populations.
Eating Disorder Symptomology and Elormones 
One factor that may affect body dissatisfaction and eating dysfunction has received 
little study; the use o f  oral contraceptives (OCs). Use o f the oral contraceptive pill in Canada is 
widespread. A study by The Sex Information and Education Council o f  Canada polled 
approximately 1,500 women and found that 84% of all respondents had used the OC pill at 
some time in their life, with an average duration o f 6.3 years (Fisher, Boroditsky, & Bridges, 
1998). Notwithstanding the fact that large numbers o f women are using oral contraceptives for 
long periods o f time. Douma and colleagues say, “the emotional and sexual side effects o f  OC 
use are largely ignored in the research literature” (Douma, Husband, O ’Donnell, Barwin, & 
Woodend, 2005, p .369). Fast research on the mood and behavioural effects o f combined OCs 
has not been helpful in delineating their effects due to huge changes in the OC compounds and 
methodological flaws in the research (see reviews by Kahn & Halbreich, 2001 ; Oinonen & 
Mazmanian, 2002).
Oral contraceptives are composed o f  synthetic estrogens and progestins (see review by 
Dickey, 2000). Monophasic OCs contain constant levels o f  estrogen and progestin throughout 
the 21-day pill period, while biphasic and triphasic OCs (i.e., multiphasic OCs) have hormone 
levels that vary from week to week. The biological activity o f  an OC comes from it’s estrogen 
and progestin composition (see review by Dickey, 2000). As a result, each brand o f  OC will 
have a different biological effect due to the variation in type and amount o f  estrogens and 
progestins. In addition, it appears that plasma levels o f hormones vary in women following oral 
administration, such that women may have different levels o f  circulating hormones after taking
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the same dose o f  oral contraceptive (de Wit, Schmitt, Purdy, Richard, & Hauger, 2001). Thus,
the impacts o f OCs on women are highly variable and not easily judged by type or brand o f
OC.
As Klump and colleagues (2006) point out, epidemiological evidence is strong in 
suggesting a role o f  gonadal hormones in the development o f  anorexia and bulimia nervosa. 
Greater than 90% o f cases o f anorexia and bulimia occur in females, and these disorders rarely 
occur before puberty or after the age o f 40 (American Psychiatric Association, 2000), 
suggesting that the higher estrogen and progesterone associated with the reproductive years 
may play a role. In addition, the heritability demonstrated for eating disorders is only 
significant in girls who have reached puberty (Klump, McGue, & lacono, 2003), and bulimic 
symptoms are significantly greater after menarche (Rowe et ah, 2002). There are at least two 
ways in which OC use might have a pharmacological effect on body dissatisfaction and eating 
dysfunction. The first is due to a direct connection between the exogenous gonadal hormones 
or accompanying alteration o f endogenous hormone levels and both disordered eating and 
body image; and the second is an indirect route whereby estrogens and progestins alter mood 
and physical well-being, which might then impact body image and eating. A study examining 
whether women who experience OC side effects also experience greater eating disorder 
symptoms could further elucidate the relationship that has been suggested between gonadal 
hormones and the etiology o f anorexia and bulimia.
A number o f studies have demonstrated links between various hormones and either 
body image or eating dysfunction. Altabe and Thompson (1990) examined fluctuations in body 
image over the menstrual cycle and found that the higher a participant’s menstrual distress, as 
measured by the M enstmal Distress Questionnaire (MDQ), the higher her eating dysfunction, 
as measured by the Eating Disorder Inventory - Drive for Thinness subscale (EDI-DT; Gamer, 
1983). They also found a main effect for menstmal phase, wherein participants experienced
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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greater body image dissatisfaction (EDI -  Body Dissatisfaction subscale) during the
premenstrual phase when compared with the intermenstrual phase. Participants also
experienced greater dissatisfaction with their physical appearance during the premenstrual
phase, as measured by the 18-item Body Self-Relations Questionnaire -  Physical Appearance
subscale (Noles, Cash, & Winstead, 1985). In addition, participants with higher menstrual
distress had poorer body image than those with lower menstrual distress. These results suggest
that hormone levels may affect levels o f body dissatisfaction and eating dysfunction in certain
individuals.
A study conducted by Gladis and W alsh (1987) examined the relationship between 
menstrual cycle phase and frequency o f binge eating in 15 normal weight females with 
bulimia. They found a modest but significant rise in binge behaviour during the premenstrual 
phase. Lester and colleagues (2003) also found correlations between bulimic symptomology 
and menstrual cycle phase. They examined women with bulimia and controls over an entire 
menstrual cycle and found that binge frequency in the experimental group increased 
significantly in the mid-luteal and premenstrual phases. This body o f  research points to phasic 
increases in both dysfunctional eating behaviours and body dissatisfaction. These effects 
appeared in the latter half o f the cycle during the mid-luteal phase when progesterone levels are 
peaking and estrogen levels are moderately high, and during the premenstrual phase when both 
estrogen and progesterone levels are falling.
Human and animal studies have shown that the activational effects o f  estrogen can 
decrease appetite and increase physical activity (see review by Eckel, 2004). It is believed that 
estrogen regulates the growth o f fat and fat-free tissues, and is also involved in energy 
expenditure (Richard, 1986). As suggested by Liang and colleagues (2002), estrogen appears to 
have a role in obesity because in times o f lowered estrogen, such as during menopause, obesity 
increases but can be reversed by estrogen replacement. The neuronal systems involved in the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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anorexic effects o f estrogen have been hypothesized to be carried out by its impact on a
number of substances, including neuropeptide Y, dopamine, endorphins, and substance P, all o f
which have strong influences on feeding behaviour (see review by Young, 1991).
Klump and colleagues (2006) examined the activational effects o f estrogen on 
disordered eating in two small samples o f non-clinical young adult females. All participants 
were tested during the follicular phase o f the menstrual cycle and were not using oral 
contraceptives or any other hormonal medication. Salivary estradiol samples were analyzed 
using radioammunoassay and enzyme immunoassay. A moderate positive correlation between 
estradiol levels and disordered eating was discovered, indicating that higher circulating levels 
o f estrogens increase the probability o f disordered eating. These findings suggest that estrogen 
plays a role in disordered eating and that the introduction o f an exogenous estradiol with the 
oral contraceptive pill may result in an increase in eating dysfunction.
Other studies have demonstrated a decrease in food intake during the periovulatory 
phase in cycling women (e.g., Gong, Garrel, & Calloway, 1989). At that point in the menstrual 
cycle estrogen levels are high and progesterone levels are low. According to Geary (2001),
“the concentration o f plasma estrogens, especially estradiol, correlate inversely with feeding 
during many physiological states, whereas the concentrations o f other HPG hormones do not” 
(p. 1252). It has been observed that the periovulatory decrease in appetite in women follows 96 
hours after an increase in estradiol, which suggests that estradiol activates a physiological 
cascade dependant on genetically controlled protein synthesis (see review by Geary, 2001).
This suggests that women taking a multiphasic OC may show more restrained or disordered 
eating than those taking a monophasic OC, given that increases in estradiol will occur. Studies 
suggest that the inhibitory effect o f estradiol on appetite is mediated by cholecystokinin and 
serotonin satiety signaling systems (see review by Eckel, 2004). The action o f  serotonin
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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appears to involve the 5-HT2c receptor, while the effects o f  estradiol appears to involve both 
the alpha and beta receptors.
Progesterone, which has been observed to block the anorexic effects o f  estrogen (see 
review by Young, 1991), has also been implicated in the pathology o f eating disorders. 
Progestins have been used to stimulate appetite in cancer patients (Yavuzsen, Davis, Walsh, 
LeGrand, & Lagman, 2005), and are believed to contribute to overeating in women with 
premenstrual tension (Giannini, Price, Loiselle, & Giannini, 1985). M onteleone and colleagues 
(2001) examined plasma levels o f  neuroactive steroids in drug-free women w ith anorexia and 
bulimia, and matched controls. Patients with anorexia and bulim ia exhibited significantly 
higher plasma levels o f the progesterone metabolite allopregnanolone (ALLO; 3a, 5a-THP), 
dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S) and cortisol, but significantly 
lower levels o f I7(3-estradiol. Increases in ALLO are also seen in people suffering from anxiety 
disorders (Strohle et ah, 2002). DHEA and DHEA-S are precursors to testosterone and 
estrogen, and are known to affect feeding, mood and cognition, likely via gamma-aminobutyric 
acid (GABA) and serotonin (5-HT) receptors (Rupprecht & Holsboer, 1999). It has been 
suggested that these differences in steroid hormones in eating disorder patients may be the 
body’s attempts to counteract aberrant feeding and mood (Monteleone et ah, 2001).
To examine whether the changes in neuro active steroids in anorexia and bulim ia 
patients are due to nutritional deficits, Monteleone and colleagues (2003) studied females with 
binge eating disorder (BED). These patients share eating pathology such as bingeing, but do 
not suffer from malnutrition. W hen obese women with BED were compared with obese 
women who do not binge, the former showed increased plasma levels o f neurosteroids 
including ALLO, DHEA, and DHEA-S. Similar results were found when non-obese BED 
patients were compared with non-bingeing, healthy subjects. These results are consistent with 
animal studies in which ALLO has been shown to induce hyperphagic effects in food-deprived
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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rats (Reddy & Kulkami, 1998). These studies suggest that progesterone metabolite levels may
be associated with dysfunctional eating.
Hormonal links with eating disorder symptoms have been demonstrated by an increased
severity o f symptoms in the mid-luteal and premenstrual phases o f  the menstrual cycle (Altabe
& Thompson, 1990; Gladis & W alsh, 1987; Lester et al., 2003). These points in the cycle
correspond to estrogen and progesterone levels that are either relatively high or dropping. High
levels o f estrogen have been associated with decreased appetite (Gong et ah, 1989) and
increases in disordered eating (Klump et ah, 2006). Conversely, increased levels o f the
progesterone metabolite ALLO have been found in patients with anorexia, bulimia, and binge
eating disorder (Monteleone et ah, 2003; Strohle et ah, 2002). W hile the impact o f  the
cumulative effect o f these altered hormone levels is not yet clear, it seems likely that estrogen
and progesterone are involved in the occurrence o f  disordered eating.
Eating Disorder Symptomology and Serotonin 
As suggested above, oral contraceptives may have indirect effects on eating disorder 
symptomology due to physical and mood side effects. A number o f OC users experience mood 
and physical side effects (see review by Oinonen & Mazmanian, 2002). The side effects (e.g., 
depression, sadness, weight gain, swelling o f the breast or abdomen) may increase body 
dissatisfaction and eating dysfunction. According to Rubinow, Schmidt, and Roca (1998), 
research demonstrates that certain women, (e.g., those with a history o f  PMS), are differentially 
sensitive to the mood-disturbing effects o f gonadal hormones. They state that despite similar 
plasma levels o f gonadal hormones, there is a correlation between mood disturbance and 
ovarian hormones only in women with a history o f PMS. Thus, certain women appear to have a 
predisposition to hormonal mood effects. The impact o f hormonai mood effects m ay be 
particularly important in eating disorder symptoms, given the link between eating disorders and 
depression.
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A 1994 study by Cash examined the structure o f the body image construct using a
factor analysis o f  11 body image measures compieted by 279 college women. The results show 
that there is a distinct evaluative or affective component, as well as a cognitive-behavioural 
investment component to body image. A study by  Rowe and colleagues (2002), examined 
bulimia symptoms and their relation to psychiatric symptoms in a large sample o f twins. They 
found that bulimic symptomology was strongly and significantly related to both depression and 
anxiety symptoms. These relationships were not accounted for by differences in BMI. Thus, 
negative affective states appear to be relevant to both body dissatisfaction and dysfunctional 
eating.
A French study examined correlations between scores on the Eating Disorder Inventory 
(EDI) and Beck Depression Inventory (BDI; BizeuI, Brun, & Rigaud, 2003). They found that 
EDI scores were higher in patients that were severely depressed, versus less-depressed and 
non-depressed subjects. Furthermore, scores on the BDI correlated with all eight EDI 
subscales, especially two related specifically to body image: Drive for Thinness and Body 
Dissatisfaction. These data suggest that there is an interaction between depression and body 
image, and that the presence o f depressive symptoms may exacerbate eating disorder 
symptomatology.
A study which examined comorbidity in eating disorder patients found that 50% o f the 
248 subjects also suffered from an affective disorder (Milos, Spindler, Buddeberg, & Crameri, 
2003). M ajor depressive disorder was the most common affective disorder present, found in 
35% o f  the sample. There is also evidence that anorexia nervosa and major depressive disorder 
m ay have a shared genetic risk. The results o f a population-based twin study by Wade, Bulik, 
Neale and Kendler (2000), indicates that the proportion o f shared genetic variance between 
anorexia and depression is 34%. They concluded that there are both common and unique
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genetic effects involved in the etiology o f  these disorders. Common etiological factors could 
therefore be involved in both mood and eating disorder symptoms.
In addition to the commonly-known link between serotonin and depression, there is 
also evidence that serotonergic action is related to feeding behaviours and satiety (Frank et ah, 
2001; Monteleone, Branbilla, Bortolotti, & Maj, 2000). This is further evidence for a link 
between mood and eating disorders at the biological level. Research has shown that an increase 
or direct activation o f 5-HT receptors tends to reduce food consumption whereas a decrease in 
5-HT neurotransmission leads to increased food consumption and weight gain (see review by 
Kaye, Gendell & Strober, 1998). Studies have demonstrated disruptions in serotonergic 
neurotransmission in individuals during anorexic and bulimic episodes. For example, a study 
by M onteleone and colleagues (2000) concluded that impaired serotonergic transmission 
occurs in underweight anorexic patients and bulimic patients with a high frequency o f 
bingeing, but not in patients with milder bulim ia or binge-eating disorder patients. Hence, 
serotonin could be involved in the etiology o f dysfunctional eating symptoms.
To determine whether altered serotonin activity in anorexics is simply a byproduct o f 
m alnutrition and low weight, Frank and colleagues (2001) examined restricting-type anorexic 
patients who had been weight restored in an inpatient treatment program. Meta- 
chlorophenylpiperazine (m-CPP), a selective serotonin agonist which can be used to assess 
serotonin functioning, was administered to the weight-restored anorexic patients and a group o f 
controls. The administration o f  m-CPP in the experimental group was associated w ith a 
reduction in negative mood states, distortions o f  body image and the feeling o f being too fat, 
supporting the hypothesis that disruptions in serotonin activity may contribute to the 
pathophysiology o f  anorexia. Similar results were found for bulimic patients in m-CPP studies 
(Brewerton et ah, 1992; Levitan et ah, 1997).
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Other studies have shown that despite weight restoration and improved nutrition,
disturbed eating and affective regulation as well as drive for thinness continues in a number o f
anorexic patients (see review by K aye et ah, 1998). Furthermore, women who are recovered
from bulimia continue to experience body dissatisfaction, low mood, and show abnormal
eating behaviour. Thus, altered serotonin activity appears to be involved in negative mood,
body dissatisfaction, and eating dysfunction in patients with anorexia and bulimia. This
association is likely not due to poor nutrition or low BMI.
M ood and Gonadal Hormones 
It was noted above that there is an association between eating disorder symptoms and 
mood such that eating dysfunction and body dissatisfaction tend to worsen with depression. 
This link may be important in oral contraceptive users. While many women experience either 
no mood change or a ‘leveling’ o f  m ood as a result o f  OC use, it is noted that a group o f 
women do experience an increase in negative mood and affect (see review by Oinonen & 
Mazmanian, 2002). In fact, depression is cited as one o f the most common reasons for 
discontinuing OC use (Patten & Lamarre, 1992; Rosenberg & Waugh, 1998); more than one 
study has found that approximately 30% o f women discontinue use because o f  mental effects 
(see review by Halbreich, W amback, & Kahn, 2003). It is possible, due to the connection 
between depression and eating disorders, that OC-related negative mood effects may adversely 
impact an OC-user’s body image and level o f eating dysfunction.
Douma and colleagues (2005) have reviewed evidence linking changes in estrogen 
levels with negative m ood and depression in women. M iller and Rogers (2005) explain the 
reason for the estrogen-depression link. “Estrogen has been shown to modulate the synthesis, 
release, and metabolism o f serotonin, norepinephrine, and dopamine in a way that is similar to 
antidepressants (p. 35)” . They suggest that with such a complex and wide-reaching relationship 
between estrogen and important mood-related neurotransmitters like serotonin, fluctuating
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levels o f  estrogen are likely to im pact mood. According to Arpels (1996) when estrogen levels
in the brain drop below what is required, a woman may experience dysfunction in mood,
memory and cognition.
The ways in which estrogen modulates the effects o f neurotransmitters such as 
serotonin continue to be clarified by human and animal studies (see review by Joffe & Cohen, 
1998). Estrogen binds to intracellular receptors to carry out it’s wide-ranging cellular effects, 
such as on the transcription o f genes which encode enzymes that regulate a num ber o f 
pathways, including those involved in the synthesis and metabolism o f neurotransmitters and 
neuropeptides. It is suggested by Rubinow and colleagues (1998), that estradiol regulates 
serotonin receptor number and function, thus altering the response to serotonin and drugs that 
modulate serotonin. Estradiol could therefore alter both satiety and mood via it’s effects on 
serotonergic activity.
Further evidence for this is found in sex differences in serotonin function. W hen 
compared with men, women have been reported to have decreased serotonin synthesis in the 
brain, increased serotonin metabolites in the cerebrospinal fluid, and decreased ability to bind 
5-HT2A receptors in certain areas o f the brain (see review by Joffe & Cohen, 1998). Joffe and 
Cohen (1998) also report that women with histories o f  depression are also m ore sensitive to 
recurring episodes o f  depression during times w hen gonadal hormones are fluctuating, such as 
pregnancy and menopause. Thus, it has been suggested that certain women are vulnerable to 
mood difficulties that are either caused or revealed by regular fluctuations in gonadal 
hormones.
W hile more attention has been placed on estrogen as a modulator o f mood, 
progesterone and it’s metabolites have also been shown to be involved in depression and 
anxiety. Progesterone is synthesized in the CNS and can also be synthesized in the periphery 
and transported into the brain, where it is converted to 5a-dihydroprogesterone (5a -DHP) and
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ALLO (Monteleone, 2003). This family o f neuroactive steroids have both genomic and
nongenomic effects (see review by Guidotti & Costa, 1998). For example, ALLO affects
neural excitability at G ABA and glutamate receptors, and progesterone and 5a-DHP affect
gene expression and neuronal plasticity. According to Andreen and colleagues (2005), ALLO
has been reported to have bimodal effects; low doses decrease concentration and induce
negative mood and aggression while high doses have anxiolytic, sedative, and hypnotic effects.
These effects can be due to endogenous progesterone from the corpus luteum or exogenous
progestins from OCs (Arpels, 1996).
It also appears that, like estrogen, progesterone and it’s metabolites affect some women 
differently. For example, premenstrual dysphoric disorder (PMDD) is believed to be related to 
progesterone drops in the late luteal phase. However, affected women have similar absolute 
levels o f  progesterone when compared to unaffected women (see review by Sundstrom 
Poromaa, Smith, & Gulinello, 2003). Thus, similar progesterone levels must have different 
effects in different women. Various progesterone metabolites appear to function differently and 
perhaps even with opposite effects. For example, one study found that higher levels o f  5a-DHP 
and ALLO in the luteal phase were associated w ith improved PMS symptoms, while higher 
levels o f  pregnenolone were related to worse mood symptoms (W ang et ah, 1996). Clearly, 
examinations o f progesterone effects on mood m ust look at variables other than just 
progesterone levels (e.g., amount and type o f metabolites).
Decreased levels o f ALLO have been linked with anxiety and depression in various 
models o f  mood disorders, according to Sundstrom-Poromaa and colleagues (2003). Andreen 
et al. (2005) noted that studies o f hormonal contraceptives and hormonal replacement therapy 
(HRT) have indicated that women tend to experience the most negative mood side effects 
when taking smaller doses o f progestins. The effects o f high levels o f ALLO have also been 
witnessed in human studies. In research by de W it and colleagues (2001), intramuscular
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injections o f  progesterone resulted in ALLO levels beyond those seen in the menstrual cycle. 
Participants experienced sedation and decreased ratings o f vigor and friendliness. W hen 
progesterone was administered orally, high levels o f  ALLO correlated with fatigue, confusion, 
and decreased verbal memory and symbol copying in female subjects (Freeman, 1993). Thus, 
the bimodal effects o f progesterone described previously are apparent in these hum an studies.
The study by Andreen and colleagues (2005) examined the levels o f ALLO, 
progesterone and pregnenolone and symptoms o f negative mood in women receiving HRT. 
Plasma progesterone, ALLO and pregnenolone concentrations increased with progesterone 
dose. Significantly more negative mood symptoms were observed during the progesterone 
phase compared to treatment with unopposed estrogen or placebo. W omen who had medium 
levels o f ALLO (similar to concentrations seen in the luteal phase o f  ovulating women), 
experienced significantly more negative mood and physical symptoms compared to women 
with high or low levels. This study also provided evidence that the progestin content in HRT 
m ay induce cyclical mood and physical effects, similar to those observed in the luteal phase o f 
the ovulatory cycle and in premenstrual dysphoric disorder.
Two studies have indicated reduced concentrations o f  3a neuro active steroids such as 
ALLO, and increased levels o f it’s stereoisomer, 3(3, 3 a-tetrahydropro gesterone (3(3, 3a-THP), 
in the plasma and cerebrospinal fluid o f depressed patients (Romeo et ah, 1998; Uzunova, 
1998). Increased levels o f  3(3, 3a-THP and reduced levels o f ALLO have also been observed in 
patients with anxiety disorders such as panic disorder (Strohle et ah, 2002). In two trials, taking 
fluoxetine over several weeks increased levels o f 3a neuroactive steroids (Romeo et ah, 1998; 
Uzunova, 1998). Research by Fser and colleagues (2006) further supports the finding that 
SSRIs may work directly on 3a-reduced neuroactive steroids (e.g., ALLO, 3a, 513- 
tetrahydroprogesterone). Guidotti and Costa (1998) have hypothesized, based on animal and 
human studies, that fluoxetine reduces the conversion o f ALLO to 5a-DHP, thus increasing
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ALLO levels. In their study, Guidotti and Costa (1998) found that treatment o f unipolar
depression with fluoxetine increased levels o f ALLO, and the greatest increases were found in
subjects with the most improvement o f  depressive symptoms. These studies suggest that
reduced levels o f the progesterone metabolite ALLO are associated with negative affect.
Research supports a relation between depressive symptoms and eating disorder 
symptomatology. Gonadal hormones m ay be underlying this relationship, given that estrogen 
modulates serotonin, an important mood-related neurotransmitter. In addition, decreased levels 
o f certain progesterone metabolites appear to be related to negative m ood in some people. 
Therefore, women who experience negative mood side effects caused by the introduction of 
exogenous hormones via the oral contraceptive pill, could also experience an increase in 
disordered eating and body dissatisfaction.
Genetics and Eating D isorder Symptoms
Studies have demonstrated that eating disorders, including anorexia and bulimia 
nervosa, have a heritable component. Gorwood and colleagues (2003) examined numerous 
controlled family studies o f  anorexia nervosa and found a heritability o f  approximately 70%
{h^ = 0.69, SD  = 0.04). According to Bulik (2004), “the vast majority o f  controlled family 
studies have found a significantly greater lifetime prevalence of eating disorders among 
relatives o f eating-disordered individuals in comparison to relatives o f  controls (p. 169).” That 
is, relatives o f individuals with anorexia nervosa are 11.3 times m ore likely to have anorexia 
than relatives o f controls, and relatives o f individuals with bulimia are 4.4 times more likely to 
have bulimia than controls. Evidence also points to transmissible risk factors; relatives o f 
people with anorexia or bulimia are more likely to have any eating disorder compared to 
controls. An overlap in genetic vulnerability has also been suggested for anorexia, bulimia, and 
internalizing disorders such as depression (Rowe et ah, 2002). In light o f  this overlap, it seems
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reasonable to examine the genetics o f  body dissatisfaction and eating dysfunction, symptoms 
that both anorexia and bulimia share.
Twin studies, which allow the teasing apart o f  genetic and environmental effects have 
been conducted for both anorexia and bulimia. Heritability estimates for anorexia derived from 
three separate studies ranged from 0.48 to 0.74, although large twin studies o f  anorexia are 
difficult due to the rarity o f  the disorder (Bulik, 2004). Population-based studies o f  bulimia 
have suggested a moderate contribution o f  additive genetic effects. One twin study has been 
conducted that examined the genetic transmissibility o f  body image versus the presence o f a 
particular eating disorder (Wade, W ilkinson & Ben-Tovim, 2003). This Australian study 
assessed the body image o f 894 pairs o f  female twins using the Body Attitudes Questionnaire 
and found that there is a sizeable genetic component to body image, which is relatively 
independent o f body mass index. The researchers concluded that, “body attitudes are primarily 
mediated through genes rather than the environment” (Wade et ah, 2003, p. 1401).
A second twin study was conducted which examined eating attitudes in a sample o f 
normal twins. Rutherford, McGuffm, Katz, and M urray (1993) administered the Eating 
Attitudes Test (EAT) and the Eating Disorder Inventory (EDI) to 147 monozygotic and 99 
dizygotic twin pairs. They found a heritability value o f  41% for the EAT total score and 42% 
for a ‘dieting’ factor derived from the EAT. For the EDI scores they found heritability values 
o f 52% and 44% for the body dissatisfaction and drive for thinness subscales, respectively. 
These twin studies demonstrate that sub-clinical eating disorder symptoms may have a 
substantial genetic component.
Evidence from family studies o f  eating disorders suggest that it is not anorexia or 
bulimia as such that is being inherited. It has been suggested that what specifically is being 
inherited are affective disorders (e.g., depression), autistic-type symptoms, or cluster C 
personality disorders (see review by Gillberg & Rastam, 1998). Treasure, Collier and Campbell
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(1997) suggest that a ‘drive for thinness’ is inherited, a component o f  eating dysfunction
examined in the present study. The previously-mentioned adolescent twin study by Rowe and
colleagues (2002) found that bulimic symptoms, such as bingeing and purging, w ere strongly
heritable in a non-clinical population.
Specific genes that have been associated with anorexia and bulimia include the 
serotonin receptor and transporter genes, the estrogen receptor genes, and the norepinephrine 
transporter gene (Kas, Van Elberg, Van Engel and, & Adan, 2003). Although a num ber o f 
specific genes have been studied, results are often conflicting and thus far no particular genes 
have been consistently implicated. W hile a significant amount o f research has been conducted 
into the specific genes pertinent to eating disorders, the genes relevant to body and eating 
attitudes have not been given as much attention. In addition, few studies have examined the 
association o f specific gene polymorphisms with eating disorder symptoms in a normal female 
population.
Serotonin Genes
Gorwood and colleagues (2003) state that altered serotonin neurotransmission is 
generally understood to occur in anorexia patients. A study by Goodwin, Fairbum, and Cowen 
(1987) suggests that dieting changes serotonergic function in women, but not men. They found 
that brain 5-HT activity was reduced in female dieters who lost weight. A study by  Bailer 
(2004) and colleagues used PET scans to examine the 5-HT2a receptor in the brains o f  women 
recovered from anorexia and bulimia, as well as controls. The eating disorder group had 
significantly lower 5-HT2A receptor binding potential, and this was negatively correlated with 
drive for thinness. Patients with anorexia have also been recorded as having reduced levels o f 
5-HT metabolites in their cerebrospinal fluid (Goodwin et ah, 1987). Goodwin and colleagues 
hypothesize that if  the same changes occur in normal female dieters it may point to a
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relationship between dieting and supersensitivity o f post-synaptic receptors causing reduced 5-
HT availability.
While consistent results have not been achieved across all studies, there is a body o f 
research showing associations between various serotonin genes and eating disorders. Findings 
for regions o f the 5-H T ib , 5-H T2c, S -H T ia  genes, and 5-F IT t gene promoter region w ill be 
reviewed, along with the region examined in the present study, 5-HTx intron 2. Serotonin 
receptor gene IB, aside from being associated with anorexia, has also been reported to be 
associated with minimum lifetime body mass index in women with bulimia nervosa (Levitan et 
al., 2001). Bulimic patients with a particular polymorphism on the 5-H T ib  gene had a 
significantly lower minimum lifetime BMI. The authors suggest that bulimic patients with this 
genotype may be more vulnerable to anorexia. Another study examining allelic variations in 
serotonin receptors, this time in the S-HTic receptor gene, found that the Ser23 allele was 
significantly related to susceptibility to anorexia and severity, as it was related to minimum 
body mass index (Hu, Geotakis, Li, Karwautz, Treasure, & Collier, 2003). The association 
between these two genes and both eating disorders and body mass index could suggest a role 
for serotonin genes in drive for thinness.
According to Gorwood and colleagues (2002), the serotonin 5-HT2a receptor is more 
sensitive to estrogen than other serotonin receptors, and the 5-HT2Agene shows the strongest 
association to anorexia than any other candidate gene studied thus far. Several studies have 
found the -1438G/A polymorphism to be significantly related to eating disorders. A cormection 
was found between anorexia and the A allele o f polymorphism -1438G/A on the 5-HT2a gene 
by Collier and colleagues in 1997. The A allele was also examined in an Italian study by Ricca 
and colleagues (2002). They found a significant association between the A allele and 
restricting anorexia, and a slight positive association between the bulimic subgroup and the A 
allele. A significant link between the A allele and restricting-type anorexics when compared to
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controls and other anorexics and bulimics was also found in a study by Nacmias and colleagues
(1999). Another study that examined the -I438G /A  polymorphism measured behavioural
impulsiveness and serotonin function in women with bulimia, following evidence that traits
such as impulsiveness, hostility and submissiveness correlate with reduced prolactin responses
to m-CPP (Bruce et ah, 2005). The results o f  the study indicated that bulimics with the GG
genotype demonstrated significantly less post-synaptic serotonin activity and greater overall
impulsiveness.
Ricca and colleagues (2004) examined the -I438G /A  polymorphism on the 5-HT2a 
gene in a wide spectrum o f eating disorder patients using continuous measures o f 
psychopathology. Scores on the Weight Concern and Shape Concern subscales, as well as the 
total score on the Eating Disorder Examination were significantly different between genotypes. 
The overall results suggest that being homozygous for the A allele could be a risk factor for 
greater weight and shape concern, as well as bulimia and the restricting type o f anorexia.
In addition to symptomatology, personality dimensions related to anorexia were also 
examined for a genetic link to the -1438G/A polymorphism on the 5-HT2a gene. Rybakowski 
and colleagues (2006) discovered a statistical trend towards significance for the association o f 
the A allele with anorexia. There was also a significant association between this polymorphism 
and two temperament traits. Subjects with the A/A genotype scored significantly higher on 
harm avoidance than those with the G/G genotype, and A/A homozygotes scored lower on 
reward dependence than heterozygotes. The authors indicate that high harm avoidance and low 
reward dependence have been shown to be characteristic o f the restricting type o f  anorexia, 
which has also been associated with the 5-HT2a gene. Therefore, the 5-HT2a gene m ay be 
associated with particular types and subtypes o f eating disorders, symptomatology, and 
personality traits related to eating disorders.
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As discussed by Collier and colleagues (1996), the serotonin transporter is responsible
for active re-uptake o f serotonin after its release from neurons in the brain. Based on evidence
from neurobiological studies, it has been suggested that polymorphisms on the serotonin
transporter gene relate to differences in transcriptional efficiency o f  the serotonin transporter
(Fiskerstrand et ah, 1999; MacKenzie & Quinn, 1999). The serotonin transporter gene (5-HTt)
has been associated with numerous affective disorders, including depression, anxiety, and
bipolar disorder (Gorwood et ah, 2003). Studies have also associated the serotonin transporter
gene with neuroticism, a personality trait which has also been linked with anorexia nervosa
(Gorwood et al, 2003). There have been five studies conducted which attempted to link a
polymorphism on the promoter region o f the 5-HTt (5HTTLPR) gene with anorexia (Fumeron
et ah, 2001; Hinney et ah, 1997; M atsushita et ah, 2004; Sundaramurthy, Fieri, Gape,
Markham, & Campbell, 2000; Urwin et ah, 2003) and only one that has examined it’s
association with bulimia (Fauzurica et ah, 2003).
In 1997, Hinney and colleagues examined the 5HTTLPR alleles and genotypes o f
obese, underweight, and anorexic participants. They found no association between any o f  these
classifications and the 5HTTFPR. Urwin and colleagues (2003) were also unsuccessful in
finding a link between 5HTTFPR and anorexia. They examined 106 Australian trios and found
no increased risk o f  anorexia associated with any o f the genotypes. They also found no
association with anorexia subtype, age at onset, or minimum lifetime BMI.
Sundaramurthy and colleagues (2000) examined the long and short variants o f
tandemly repeated sequences on the prom oter region o f the 5-HTt gene. The frequency o f  the
short allele, which has been shown to reduce the transcriptional efficiency o f  5-HTt such that
5-HT uptake occurs at half the rate o f the long allele, was greater in the anorexia patient group
when compared with controls. However, this was not statistically significant. The short allele
was significantly more frequent in anorexia patients, lower in normal weight controls, and
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lowest in overweight controls in a study by Fumeron and colleagues (2001). The SS genotype
was also significantly related to lower intake o f several important nutrients, although only
carbohydrate intake reached significance. This result remained significant even after the
anorexic subjects were excluded.
A meta-analysis was conducted by Gorwood (2004) to re-assess the contribution o f the 
serotonin transporter gene in anorexia. All four o f the above described studies on the 
5HTTFPR were included. Only one in four, the study by Fumeron and colleagues (2001) had 
found an association between 5HTTFPR and anorexia. Overall, the results support a signifieant 
role for the short allele in anorexia nervosa, even after the moderate heterogeneity between 
samples is taken into consideration. Thus, the serotonin transporter gene promoter region may 
be associated with anorexia and reduced carbohydrate intake in normal and clinical 
populations.
A team o f Japanese researchers also examined the 5-H Tj prom oter region 
polymorphism in 195 female Japanese eating disorder patients and 290 matched controls 
(Matsushita et al., 2004). The 5FITTLPR short allele (S) was found in significantly more 
anorexia patients than control subjects. Additionally, they observed that patients in the eating 
disorder group who were initially diagnosed with anorexia and continued to be diagnosed three 
years later were significantly more likely to have the S allele. Thus, the 5HTTFPR m ay have 
some relation to the course o f disease in anorexia.
Matsushita, Makamura, Nishiguchi, and Higuchi (2002), also examined the distribution 
o f the 5HTTFPR genotypes and alleles with respect to scores on the FAT. The scores o f  179 
female Japanese college students were designated as either high or low. Current, m inim um  and 
maximum BMIs did not differ between groups. They discovered that the FF  genotype and the 
F  allele were significantly more frequent among those who scored high on the FAT, with an 
odds ratio o f 2.47 (95% Cl, 1.34 - 4.56). While the S allele has been associated w ith eating
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disorders in previous studies, the authors point out that the higher frequency o f the S allele in 
Japanese people than in Caucasians may play a role. Regardless, this study indicates that the 
promoter region o f the serotonin transporter gene may be associated with eating disorder 
symptoms in a normal population o f female students.
Lauzurica and colleagues (2003) examined the 5HTTLPR and a polymorphism on the 
intron 2 o f the 5-HTt in a population o f patients with bulimia. The intron 2 polymorphism is a 
variable number tandem repeat (VNTR) o f a 16/17 base pair element, o f  which nine to twelve 
copies are usually found. Lauzurica and colleagues found no significant association between 
the bulimic group and either o f the polymorphisms, regardless o f whether or not the women 
had previously suffered from anorexia. Interestingly, when they jointly considered the 
genotypes it was discovered that bulimics were significantly more likely than the control group 
to have the S/S genotype in the promoter region and the 10/12 genotype in the intron region.
As previously stated, the 5-HTt gene acts as a transcriptional regulator, with the 12 allele 
having higher enhancing-like properties than the 10 allele (Fiskerstrand et al., 1999; 
M acKenzie & Quinn, 1999). Thus, although Lauzurica et al. did not find an association with 
bulimia, the presence o f the Tower activity’ 10 allele m ay increase risk for eating and mood 
disorders.
There has only been one study to examine the association between the intron 2 region 
o f  the 5-HTt gene and eating disorders (Lauzurica et ah, 2003). However, this region has been 
examined in connection with other mental health and personality constructs that are relevant to 
eating disorders. Some o f these findings will be discussed as they were a guide for developing 
hypotheses in the present study. The polymorphism on the intron region o f 5-HTt gene was 
examined for links with major depression by Ogilvie and colleagues in 1996. They compared 
39 unipolar depressed patients, 44 bipolar patients, and 193 controls. The presence o f  nine 
copies o f  the repeat (STin2.9 allele) was significantly associated with risk o f unipolar
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depression. Gutierrez and colleagues (1998) examined 74 patients who had been diagnosed
with major depressive disorder with melancholia (MDDM) and 84 controls. W hile allele and
genotype frequencies did not differ between groups, when the researchers examined a
haplotype that consisted o f the S allele o f the promoter region and the 10 allele (STin2.10
allele) o f  the intron region they found that individuals with both alleles were significantly more
likely to have MDDM. Thus, repeats in the second intron o f  5-HTt seem to increase risk for
depression.
In addition to eating disorders, reduced serotonin neurotransmission is also reported to 
relate to suicidal behaviour. In 2003, Hranilovic and colleagues performed the first study that 
examined a possible link between suicidality and polymorphisms on the second intron o f the 5- 
HTt gene. They hypothesized that suicide victims would be more likely to possess the 10 
allele, based on its connection with reduced serotonin enhancement compared to the 12 allele. 
They obtained blood samples from 135 Croatian suicide victims and compared them to 
samples from 299 controls w ithout a history o f  neuropsychiatrie disorders. A significant 
association was found between the 10 allele and suicidality which was lost after correction for 
multiple comparisons. A year later the same group o f researchers attempted to replicate the 
above study w ith a larger sample (Jemej et ah, 2004). Their experimental group was increased 
to 192 suicide victims and their control group was increased to 377 blood donors. They 
examined combinations of 5-HTt gene intron 2 region and the tryptophan hydroxylase gene, 
both o f which have Tower activity’ alleles. The results indicated that the suicide group was 
significantly more likely to possess one or both o f the Tower activity’ genotypes (i.e., the 
10/10 5-HTt genotype) when compared with controls.
Based on the link between the 5-HTt gene and serotonin neurotransmission, suicidality, 
impulsive behaviour, and emotional lability. N i and colleagues (2006) viewed the 5-HTt gene 
as an excellent candidate for involvement in the etiology o f borderline personality disorder
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(BPD). They recruited 89 Caucasian patients diagnosed with BPD and 269 healthy Caucasian
controls from Toronto and central Canada. W hen they compared genotypes with and without
the 10 allele they found a significant positive association o f  the 10 repeat w ith BPD. In
addition, BPD patients had a greater frequency o f the 10 allele and a lower frequency o f the 12
allele when compared with controls. BPD, along with impulse-control problems and mood
lability, are mental disorders associated with bulimia and the binge/purge subtype o f anorexia
(American Psychiatric Association, 2000). M ilos and colleagues (2003) reported rates o f  16
and 29% for Cluster B personality disorders in samples o f anorexic and bulimic patients,
respectively. Thus, the 10 repeat may be relevant to eating disorders, given its association with
personality as well as mood.
Another study that examined personality as it relates to expression o f  the VNTR on 
intron 2 o f the 5-HTx gene was conducted by Tsai, Hong, and Cheng (2002). They examined 
the genotype and allele frequencies o f  192 healthy Chinese subjects who had completed the 
Tridimensional Personality Questionnaire (TPQ). Male subjects with the 10/12 genotype had 
significantly higher scores on the harm avoidance (HA2) subscale o f the TPQ, indicating 
higher fear o f uncertainty versus confidence, compared to males with the 12/12 genotype. 
While these results may be gender and ethnicity-specific, they are consistent with evidence that 
abnormalities in the serotonin system o f eating disorder patients may be related to particular 
personality traits such as compulsivity and harm avoidance in dietary restrictors (see review by 
Brewerton & Steiger, 2004). Greater harm avoidance (i.e., anxious avoidance and overcontrol) 
has been linked with prolonged course o f illness in anorexia (Bulik, Sullivan, Fear, & Pikering, 
2000). Thus, these studies provide further evidence that genotypes containing the 10 allele may 
be o f  importance to eating disorder symptomatology.
Other studies examining the polymorphism o f intron 2 on the 5-HTT have found links 
with the 12 allele and various mental illnesses. Collier and colleagues (1996) discovered an
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increased frequency o f  the 12 allele in patients with bipolar disorder when compared to
controls and when compared to patients with unipolar depression. The 12 allele was also
associated with presence o f an anxiety disorder in Japanese participants in a study by Ohara
and colleagues (1998). W hen specific anxiety disorders were examined on their own,
obsessive-compulsive disorder (OCD) and generalized anxiety disorder were significantly
linked with the 12 allele. In addition, the anxiety-related personality trait o f somatic anxiety
was associated w ith the 12 allele in a study by M elke and colleagues (2001). It should be noted
that there is a higher rate o f anxiety disorders, including obsessive-compulsive disorder in
eating disorder patients (Milos et ah, 2003). However, in her review o f psychiatric comorbidity
Lilenfeld (2004) states that there is no evidence o f a shared etiology o f OCD and eating
disorders based on family studies.
Based on the research indicating that reduced serotonin transmission occurs in eating 
disorders, and the discovery that shorter alleles o f the polymorphism on intron 2 o f the 5-HTt 
gene are associated with reduced serotonin activity (Fiskerstrand et ah, 1999; MacKenzie & 
Quinn, 1999), shorter alleles (10 and smaller) seem a reasonable target for the study o f  eating 
disorder symptomatology. In addition, smaller repeats have been linked with depression, 
borderline personality disorder, and suicide, which are known to be associated with eating 
disorders. Only one study has examined this gene locus with respect to eating disorders, and 
none have looked at eating disorder symptomatology.
Estrogen Genes
Due to evidence supporting a role for hormones in disordered eating, a number o f 
studies have also examined estrogen receptor genes and their association with anorexia nervosa 
(see review by Kas et ah, 2003). It has been suggested that the genetic influence on eating 
disorders may lie in genes coding for estrogen receptors or neuronal systems that are 
influenced by circulating estrogens (Klump et ah, 2006). Comings (1998) hypothesized that the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The Involvement o f 33
size o f repeats may play a role in gene regulation and thus shorter and longer alleles m ay be 
associated with different phenotypes. Rosencranz and colleagues (1998) add that greater brain 
sensitivity to estrogen mediated by estrogen receptors may predispose women to eating 
disorders.
In 1998, Rosenkranz and colleagues systematically screened the estrogen receptor beta 
gene (ESR2) for mutations in extremely obese children and adolescents, healthy underweight 
students, and patients with anorexia and bulim ia nervosa. None o f the single nucleotide 
polymorphic regions they examined could be readily associated with the anorexic or bulimic 
phenotypes. Associations between anorexia and both the estrogen receptor beta (ESR2; ESR 
beta) and estrogen receptor alpha (ESRl ; ESR alpha) genes were examined by Eastwood and 
colleagues (2002). They examined polymorphisms on those genes in 170 anorexia sufferers 
and 152 control subjects. Their results suggest no relationship between the ESRI and either the 
TA dinucleotide repeat or a single nucleotide repeat polymorphisms and susceptibility to 
anorexia. They did find an association between a particular single nucleotide polym orphism on 
ESR2 and anorexia which had been examined by Rosencranz (1998) but was not significantly 
associated in that study.
Two years later, Nilsson and colleagues (2004) examined the estrogen receptor beta 
(ESR2) gene once again, but in search o f  a connection to bulimia. They studied 76 w om en with 
bulimia and 60 controls and found a significant association between two common single 
nucleotide polymorphisms and bulimia, one o f which was not significantly associated with 
bulimia in the Rosencranz (1998) study. A lthough the results from these studies have not been 
consistent, there is sufficient evidence to continue searching the ESRI and ESR2 genes for 
association with eating disorder symptomatology.
The TA repeat on the prom oter region o f  the estrogen receptor alpha gene has been 
associated with a number o f personality traits, including neuroticism (e.g., W estberg et ah.
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2003). This is noteworthy, given the link between neuroticism and anorexia (Palmer, 2000). In
the W estberg et al. study a particular aspect o f neuroticism, somatic anxiety, was significantly
associated with the short allele o f  the TA repeat. A significant link between the TA
polymorphism and bone mineral density was found in a study o f  postmenopausal Italian
women (Becherini et ah, 2000). In another study, the TA repeat polymorphism was linked with
another ERSl polymorphism that had a positive association w ith endometriosis (Georgiou et
ah, 1999). Pritchard and colleagues (2002) found a significant sex difference in allelic
frequencies o f the TA  polymorphism, and discovered that a genotype made up o f the TA and
one other ESRI polymorphism was significantly associated with anxiety in children and
adolescents. Thus, short alleles o f  the TA repeat on the ESRI gene m ay be candidates for
association with eating disorder symptoms given the previously discovered links with
neuroticism, anxiety, and other gender-specific disorders like endometriosis.
Given the previous association between single nucleotide repeats in the ESR2 gene and 
eating disorders, the estrogen receptor beta (ESR2) appears to be an even better candidate than 
the estrogen receptor alpha (E R Sl) gene for eating disorder symptoms. In addition, estrogen 
receptor beta is believed to be involved in the anorectic action o f estrogen (Liang et ah, 2002). 
Estrogen receptor beta (ESR2) has also been associated with hormonal conditions and other 
health problems in women. For example, a CA repeat polymorphism was examined for an 
association with menopausal symptoms by Takeo and colleagues (2005). They found that 
women homozygous for the short allele and women with a genotype that combined one 
extremely short and one long allele had significantly more negative mood and physical 
symptoms. In addition, Ogawa and colleagues (2000) published two separate reports o f 
associations between the 26 repeat allele o f the CA polymorphism on the ESR2 gene and 
significantly higher systemic blood pressure and higher bone mineral density in Japanese 
women. An association between bone mineral density in premenopausal women and the 20
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allele repeat o f  the CA polymorphism was discovered in 2002 by Lan and colleagues. In
addition, ovulatory dysfunction in women with menstrual problems was linked with a single
nucleotide polymorphisms on ESR2 (Sundarrajan et ah, 2001). Serum levels o f  progesterone,
luteinizing hormone (EH), and follicle stimulating hormone (FSH) were lower in patients with
genotypes homozygous for the associated allele, indicating that this gene could be related to
levels o f endogenous hormones. Therefore, the estrogen receptor beta (ESR2) is a candidate
gene for eating disorder symptoms due to reported links with anorexia, bulimia, and other
health problems in women.
Progesterone Genes
Tsukamoto, Watanabe, Shiba, and Emi (1998) isolated the CA repeat polymorphic 
region on the progesterone receptor gene. Since then there has been no published research 
examining the link between this gene and eating disorders. This is surprising given the known 
links between progesterone, appetite, and mood. The progesterone receptor gene has been 
investigated in a small number o f studies mainly looking at cancer and endometriosis, and the 
CA repeat is usually ignored. The present study will be the first to examine the link between 
eating disorder symptomatology and the CA dinucleotide repeat on the progesterone receptor 
gene.
The Present Study
The present study will examine polymorphisms on the estrogen receptor alpha and beta 
genes, the serotonin transporter gene, and the progesterone receptor gene and their association 
with eating disorder symptoms. No studies have examined the estrogen receptor alpha or 
estrogen receptor beta genes and their possible association with body dissatisfaction and eating 
dysfunction. W hile one study did find an association between weight and shape concern and 
polymorphisms in the promoter region o f the serotonin transporter gene (M atsushita et ah, 
2002), the cun ent study will examine a 16/17 base pair repeat in the intron 2 region. Despite
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the above noted evidence o f progesterone involvement in cyclical spikes in eating dysfunction
and body dissatisfaction, previous studies have not examined the possible links between the
CA repeat on the progesterone receptor gene and these constructs. Because disordered eating
and body dissatisfaction are symptoms shared by women with both anorexia and bulimia
nervosa, it has been argued that these disorders share risk and liability factors (Kaye et ah,
1998). These shared symptoms are also widely expressed in non-clinical populations. The
present study will therefore search for associations between the above-named genes and body
dissatisfaction and eating dysfunction in a sample o f university-aged females.
The present study will also examine the possibility o f  a link between a history o f  oral 
contraceptive (OC) side effects and both body dissatisfaction and eating dysfunction. Such a 
link is hypothesized given that OCs contain estrogen and progesterone, and both estrogen and 
progesterone levels have been associated with eating disorders and eating disorder symptoms. 
Furthermore symptoms o f bulimia fluctuate with the hormonal changes o f the menstrual cycle 
(Gladis & Walsh, 1987; Lester et al, 2003). Oral contraceptives may also impact mood, which 
has a close relation to eating disorder symptoms. Body dissatisfaction and eating dysfunction 
also appear to worsen with depression (Bizeul et ah, 2003). Altered serotonin 
neurotransmission, which is understood to occur with depression, has also been demonstrated 
in eating disorders (Brewerton et ah, 1992; Frank 2001; Levitan et ah, 1997). Estrogen 
modulates serotonin neurotransmission (see review by Rubinow et ah, 1998), and progesterone 
metabolites appear to have a direct connection to mood (Andreen, 2005). Thus, the many links 
between estrogen, progesterone, and eating disorder symptoms suggest women with a history 
o f oral contraceptive side effects might have greater eating disorder symptomology.
For the present study 279 participants completed a questionnaire assessing OC use, OC 
side effects, and eating disorder symptoms. Based on this questionnaire, 144 participants were
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selected for the genetic phase o f the study. Participants in this second phase o f the study
provided a sample o f DNA to be analyzed. Six hypotheses were tested.
Hypothesis One: Oral contraceptive users who experience more negative mood or 
physical side effects will have greater body dissatisfaction than those who experience less or 
no oral contraceptive-related mood or physical side effects.
Hypothesis Two: Oral contraceptive users who experience more negative mood or 
physical side effects will have greater eating dysfunction than those who experience less or no 
oral contraceptive-related mood or physical side effects.
Hypothesis Three: Greater body dissatisfaction and eating dysfunction is associated 
with fewer repeats o f the TA polymorphism on the estrogen receptor alpha gene.
Hypothesis Four: Greater body dissatisfaction and eating dysfunction is associated with 
fewer repeats o f the CA polymorphism on the estrogen receptor beta gene.
Hypothesis Five: Greater body dissatisfaction and eating dysfunction is associated with 
shorter alleles (8, 9, and 10) o f the 16/17 base pair repeat on the intron 2 region o f  the serotonin 
transporter gene.
Hypothesis Six: Greater body dissatisfaction and eating dysfunction is associated with 
fewer repeats o f the CA polymorphism on the progesterone receptor gene.
Method
Participants
Two-hundred-seventy-nine female undergraduate students completed a questionnaire 
on “Genetic Factors Affecting W om en’s Health” (phase one). O f these, 144 women 
participated in the genetic phase o f  the study (phase two). Participants in Introductory 
Psychology courses received one bonus point for each phase o f  the study in which they 
participated. An age-range o f 18 to 25 was chosen pre hoc to create a homogenous sample o f
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young females. For demographic information on age, BMI, relationship status, and ethnicity 
for phase one and two samples, see Table 1. Table 2 illustrates the number and percentage o f 
participants who have used various oral contraceptive brands and the percentage o f  users who 
experienced mood and physical side effects. A total o f 174 women (62.6%) who completed the 
questionnaire were current or previous oral contraceptive users.
The participants in the second phase were chosen based on their history o f  OC use and 
associated negative mood side effects. Each woman fell into one o f  three groups. (1) M ood  
Change Group (n = 49). This group contained 23 previous OC users who reported negative 
mood change associated with OC use and 26 current users who reported current or previous 
mood change related to OC use. (2) No M ood Change Group (n = 43). This group contained 17 
current and 26 previous OC users who reported no history o f OC-related negative mood 
change. (3) Never Users (n = 54). This group consisted o f women who have never used 
hormonal contraceptives. These three groups o f  women were selected due to the inclusion 
criteria o f a larger study (Oinonen, 2006). However, it is noteworthy that the women in phase 2 
did not differ from those in phase 1 on the two criterion variables. There was no significant 
difference in body dissatisfaction scores between participants who did participate in the second 
phase o f the study (M =  23.89, SD  = 10.52) and those who did not (M = 24.56, SD  = 10.63), t 
(266) = 0.52,/? = .601 (two-tailed). Similarly, there was no significant difference in eating 
dysfunction scores between those who took part in the second phase (M = 1.65, SD  = 0.50) and 
those who did not (M =  1.64, SD = 0.52), t (259) = -0.11,/? = .912 (two-tailed). Thus, the phase 
two sample appears to be representative o f the phase one sample in terms o f the variables o f 
interest. This study received ethics approval by the Lakehead University Research Ethics 
Board.
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Table 1
Demographics fo r  Phase One and Two Samples
Phase One Sample Phase Two Sample 
(N = 279) (N = 144)
Means (SD)
Age 19.41 (1.80) 19.45 (1.82)
Body Mass Index (BMI) 23.59 (4.51) 23.59 (4.66)
Frequencies (%)
Relationship Status
Partner 127 (46.18) 62 (43.06)
No Partner 146 (53.09) 81 (56.25)
Ethnic Heritage “
North American
Non-Aboriginal 43 (15.64) 26(18 .06)
Aboriginal 17(6.18) 11 (7.64)
East Asian 3(1 .09) 2 (1 .39)
South East Asian 3(1 .09) 2 (1 .39)
South Asian 1 (0.36) 1 (0.69)
African 3 (1.09) 0 (0 )
South American 1 (0.36) 0 (0 )
Western European 113 (41.09) 67 (46.53)
Northern European 66 (24.00) 33 (22.92)
Southern European 85 (30.91) 39 (27.08)
British 172 (62.55) 94 (65.28)
Note.  ̂Frequencies for ethnic heritage 
heritage from that region o f the world.
are the percentage o f participants who indicated some 
For further information see Appendix G.
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Table 2
Frequency o f  Oral Contraceptive (OC) Brands and Reported Side Effects (N =  249)
Brand o f oral 
contraceptive
Frequency (%) 
o f participants 
who used OC 
brand
Frequency (%) o f 
users who reported 
mood side effects
Frequency (%) o f 
users who reported 
physical side effects
Alesse 83 (32.05) 36 (46.75) 69 (83.13)
Brevicon 1/35 1 (0.39)
Cyclen 7 (2.70)
Demulen 30 2 (0.77)
Marvelon 35(13.51) 23 (71.88) 28 (80.00)
MinEstrin 3(1.16)
MinOvral 13 (5.02) 6 (50.00) 13 (100.00)
Ortho 10/11 2 (0.77)




Diane 35 13 (5.02) 6(46.15) 7 (58.33)
Levora 5(1.93)
Ortho 7/7/7 2 (0.77)
Synphasic 1 (0.39)
Ortho-Novum 1/50 2 (0.77)
Norinyl 1 (0.39)
Yasmin 28 1 (0.39)
Note. The percentage o f users who experienced side effects was only calculated for OC brands 
that were used by more than 10 subjects. This chart is not representative o f all OC users. As 
per the selection criteria o f the larger study it does not contain a small number o f  participants 
(n -  15) who experienced positive mood effects only.
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Materials and Measures
Questionnaire
The screening questionnaire (see Appendix A) took approximately 30 m inutes to 
complete, and included sections on demographic information, reproductive history, 
contraceptive history, medical and health history, psychiatric history, and personality/mood. 
Information on contraceptive history included questions about history o f  contraceptive use, 
contraceptive choices including type and duration o f  use, reasons for discontinuing use, and 
experience o f OC side effects including mood change and physical side effects. The section on 
psychiatric history examined both individual and family history o f psychiatric disorders 
including questions about depression, bipolar disorder, anorexia, and bulimia. Depressive 
symptoms were examined using the Symptom Checklist 90 Revised (SCL-90-R; Derogatis, 
1994).The personality/mood section also included scales from the Revised N EC Personality 
Inventory (NEO-Pl-R; Costa & McCrae, 1992).
Eating D isorder Symptoms. The screening questionnaire also contained portions o f the 
Eating Disorder Inventory-11 (EDl-11) developed by Gam er (1991). This measure was o f most 
importance to the present study. The EDl-11 assesses psychological symptoms and 
characteristics common to anorexia and bulimia nervosa (Allison, 1995). The portion o f the 
test that was administered contains 23 self-report items belonging to three subscales that 
examine attitudes towards body image and eating [Drive for Thinness (DT), Body 
Dissatisfaction (BD), and Bulimia (B)].
Items on the Drive for Thinness subscale measure preoccupation with dieting and 
weight, and the presence o f an intense fear o f weight gain (Gamer, 1991). The Bulimia 
subscale measures tendencies to think about and engage in bingeing and purging behaviours. 
The sum of standardized scores on the Drive for Thirmess and Bulimia subscales provided an 
eating dysfunction score. The Body Dissatisfaction subscale measures, “dissatisfaction with the
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overall shape and with the size o f those regions o f the body that are o f  greatest concern to those
with eating disorders (i.e., stomach, hips, thighs, buttocks)” (Gamer, 1991).
The EDl-11 items are presented as statements for which the respondents choose the 
degree to which the statement is tm e about themselves from one of: 3 {always), 2 {usually), 1 
{often), 0 {sometimes), 0 {rarely) or 0 {never). However, in order to examine the full range o f 
clinical and non-clinical symptoms, the following scoring system was used: 5 {always), 4 
{usually), 3 {often), 2 {sometimes), 1 {rarely) or 0 {never). Norms are available for clinical 
populations as well as female college students (Allison, 1995). The test-retest reliabilities of 
the DT, BD, and B subscales after three weeks in a nonpatient sample o f college students were 
0.92, 0.90, and 0.97, respectively (Gamer, 1991). Gamer also reported the intemal reliability 
estimates o f those subscales have been estimated at 0.86, 0.89, and 0.90, respectively. Body 
dissatisfaction scores were calculated by summing all item responses for that subscale. Eating 
dysfunction scores were calculated by first summing item responses for the Drive for Thinness 
and Bulimia subscales, then summing the z scores o f  those subscale scores.
Oral Contraceptive Side Effects. The mood side effect score was calculated by 
summing the number o f possible mood side effects that participants indicated experiencing as a 
result o f  taking oral contraceptives. Mood side effects items were negative mood, depression, 
more irritable, sadness, more moody, cried more, and more pessimistic. Possible scores ranged 
from 0 to 7. A similar process was used to calculate the physical side effect score. This score 
reflected the number o f  the following OC side effects that participants reported experiencing: 
nausea/vomiting, breast size increase, weight gain, tiredness/fatigue, headaches, heavier 
periods, breakthrough bleeding, more menstrual cramps, painful/tender breasts, swelling o f the 
breast or abdomen, and complexion problems. A score o f zero was given if  they did not 
indicate experiencing any o f these side effects. Possible scores ranged from 0 to 11. These
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particular mood and physical side effects were chosen because they are believed to be caused 
by either an excess o f or deficiency in estrogen or progesterone (see review by Dickey, 2000).
DNA Collection and Genotyping M aterial 
DNA samples were collected using buccal swabs. Following collection the swabs were 
briefly air dried and stored in a freezer until all o f  the samples had been collected and were 
ready for genotyping. TA repeats on the estrogen receptor alpha (E R Sl) gene, CA repeats on 
the estrogen receptor beta (ERS2) gene, a 16/17 base pair repeat in the serotonin transporter (5- 
HTT) gene, and the CA repeat on the progesterone receptor (PGR) gene were examined. 
Amplification o f  the different regions was done using polymerase chain reaction (PGR) with 
fluorescently labeled primers. The fluorescently labeled regions were then analyzed by size 
using a Genetic Analyzer.
Procedure
Phase One: Questionnaire Phase
W omen attending Lakehead University were recruited to participate in a study on 
“Genetic Factors Affecting W om en’s Health”. W omen in the undergraduate psychology 
program, as well as those in other university departments were recruited during class time, 
through posters around the university, and by email. Every participant completed Consent 
Form A (Appendix B), the questionnaire, and received Debriefing Form A (Appendix C). The 
participants for the second phase o f  the study were selected from the information provided in 
the questionnaire, using the inclusion criteria defined above. The participants who were 
selected were contacted by telephone or email and the procedures involved in the second phase 
o f the study were described. A laboratory appointment was set up for participants who were 
interested in taking part.
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Phase Two: Laboratory Phase
The 30-minute laboratory session began with a re-explanation o f the procedures. 
Participants were told that they could drop out at any point in the study without explanation or 
penalty. W illing participants were asked to complete Consent Form B (Appendix D). Buccal 
swabs o f DNA were collected first. The researcher swabbed the inside o f the participant’s 
mouth using a cotton swab, and the swab was dried at room temperature and placed in a plastic 
bag. The sample was stored in a freezer at -34 degrees Celsius until all samples were collected. 
All additional procedures were completed for the larger study (Oinonen, 2006). Body 
measurements were taken using a tape measure for height and a digital scale for weight. 
Mitutoyo Electronic Digital calipers (Model MIT-500-171) were used to measure the length of 
their fingers twice. Finally, a mental rotation task was administered with a short mood 
questionnaire that was completed both before and after the task. Debriefing Form B (see 
Appendix E) was provided following these procedures. Participants were then given the option 
to complete Consent Form C (see Appendix F), which stipulates that the participant gives 
permission for researchers to contact them within the next 5 years for a follow-up study, 
providing that the study receives approval from the Research Ethics Board.
Genotyping Phase
Dr. Carney M atheson o f the Lakehead University Paleo-DNA Laboratory supervised 
the genotyping o f  the DNA samples and a lab technician performed the genotyping.
Extraction. Genomic DNA was isolated from the buccal tissue using a Chelex 
extraction method (W alsh et ah, 1991). A 10% Chelex solution was added to each sample, after 
which samples were incubated at 56 degrees Celsius and mixed at 500 rpm for approximately 3 
hours.
Amplification. Amplification was achieved via polymerase chain reaction (PCR). To a 
2.0pL sample o f genomic DNA the following solutions were added: 5.0pL PCR buffer, 2.0pL
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dNTP’s, 0.5pL each o f  forward and reverse primers, 1.5pL MgCh, 0.2pL polymerase, and
38.3pL H2O to a total o f 50.0 pL. Samples were then transferred to the Eppendorf Mastercycler
for a Hot Start at 94°C for 3 minutes. The conditions for 45 cycles consisted o f dénaturation at
94°C for 1.5 minutes, annealing at 57.7°C for 1 minute, and extension at 72°C for 2 minutes.
Final extension occurred at 60°C for 1 hour, at which point samples were held at 4°C until
fragment analysis.
Genetic analysis. To each amplified sample 0.3 pi o f size standard and 9pl o f  Hi-Di 
Formamide were added. Samples were then denatured at 95°C for 3 minutes and then 
immediately chilled on crushed ice for 2 minutes. The labeled DNA fragments were then 
analyzed by size using automated capillary electrophoresis using an ABI 3100 Automated 
Sequencer (Applied Biosystems) and analyzed using the Genescan software. This measured the 
number of repeats at each polymorphic region for each allele for each participant.
Although only the first four were included in the present study, ten unique repeat 
regions were quantified for this and the larger study; the CA repeat on the progesterone 
receptor (PGR) gene, GGC and GAG repeats on the androgen receptor (AR) gene, TA repeats 
on the estrogen receptor alpha (E R Sl) gene, CA repeats on the estrogen receptor beta (ERS2) 
gene, a 16/17 base pair repeat in the serotonin transporter (5-HTT) gene, a 31 base-pair repeat 
in the cystathionine beta-synthase (CBS) gene, TTA repeats on the aromatase gene, the CA 
repeat on the gamma butyric acid receptor alpha 5 subunit gene (GABRA5), and the CA repeat 
on the gamma butyric acid receptor alpha 3 subunit gene (GABRA3). The last nine regions 
were examined together in one multiplex and the PGR region was analyzed on its own. The 
repeat regions were amplified hy polym erase chain reaction (PCR) using fluorescently labeled 
primers.
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Data Reduction and Analyses
Multiple regressions and M ANOVAs were performed to test the six hypotheses. Based 
on the number o f analyses and the fact that they are exploratory in nature, a significance level 
o f a = 0.025 per comparison was chosen.
Analysis to Test Hypothesis One: A  history o f OC-related negative mood side effects 
and/or a history o f OC-related physical side effects is associated with higher body 
dissatisfaction in OC ever users. A m ultiple regression was performed with scores on the Body 
Dissatisfaction subscale o f the EDI-II as the criterion variable and history o f  OC-related mood 
effects and history o f OC-related physical effects as the two predictor variables (i.e., number o f 
side effects).
Analysis to Test Hypothesis Two: A history o f  OC-related negative mood side effects 
and/or a history o f OC-related physical side effects is related to higher eating dysfunction in 
OC ever users. The multiple regression was performed with the eating dysfunction score 
(created using the sum o f the z scores o f  the Drive for Thinness and Bulimia subscales o f  the 
EDI-II) as the criterion variable and history o f OC-related mood effects and history o f  OC- 
related physical effects as the two predictor variables (i.e., number o f  side effects).
Analyses to Test Hypotheses Three Through Six: Body dissatisfaction and eating 
dysfunction are significantly associated w ith fewer repeats on the estrogen receptor alpha, 
estrogen receptor beta, serotonin transporter, and progesterone receptor genes in women. In 
these MANOVAs, body dissatisfaction and eating dysfunction served as dependent variables, 
while genotype group (S/S = short/short, S/L = short/long, L/L = long/long) served as the 
independent variable. Separate M ANOVAs were performed for each o f  the four genes.
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Results
Phase One: OC Side Effects and Eating D isorder Symptoms
Data Screening
Prior to analyses, all items used in the construction o f the body dissatisfaction, eating 
dysfunction, mood side effects and physical side effects variables/scales were screened for 
accuracy o f data entry and for missing data points. No more than 5% o f  data points were 
missing for any single variable, which is suitable according to Tabachnick and Fidell (2001). In 
the calculation o f  all above-mentioned total scores, participants with missing responses were 
excluded for the relevant variable. Four cases were deleted because the participants were 
several years older than the specified age range (ages were 36, 34, 31, and 29).
Assessing M ultiple Regression Assumptions
The four main variables mentioned above were examined for violations o f the 
assumptions o f normality and linearity. To improve pairwise linearity and to reduce positive 
skewness and kurtosis, eating dysfunction was given a square root transformation. M ood side 
effects and physical side effects were logarithmically transformed to reduce positive skewness 
and kurtosis. Body dissatisfaction was reasonably normally distributed and was not 
transformed. Following the transformations all variables were reasonably normally distributed. 
No univariate outliers w ere found, as there were no z scores with an absolute value greater than 
3.29 (Tabachnick & Fidell, 2001). Variables were also screened for multivariate outliers 
through Mahalanobis distance and none were detected. Scatterplots were used to examine 
linearity o f the relationship between the variables. Linearity appeared to be satisfactory. 
Examinations o f the correlation between number o f  mood side effects and number o f  physical 
side effects ( r = .447,/? < .01 ,2 /=  159) indicated that multicollinearity was not a concern.
Note that data is reported for transformed subscales at all times unless otherwise indicated.
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Descriptive Data and Preliminary Analyses
The means and standard deviations for the four main variables, as well as the two 
variables used to create the eating dysfunction score, are reported in Table 3. The second 
column in Table 3 lists the means from this sample using the original EDI-II scoring method. 
This allows a comparison with the means o f Gamer (1991). The current sample had 
significantly lower scores on the Body Dissatisfaction Scale than did the Gamer nonpatient 
college sample, t (414) = -3.155,/? = .002. The two samples did not differ significantly in terms 
of the Bulimia subscale or the Drive for Thinness subscales (/? > .05). With respect to reporting 
a history o f the OC mood side effects items, 85 participants (53.13%) indicated that they had 
not experienced any o f  the mood side effects used to calculate the mood side effect score. 
Conversely, 75 participants (46.88%) indicated that they had experienced at least one side 
effect. For physical side effects, 40 women (23.26%) indicated they had not experienced any o f 
the physical side effects used to calculate the physical side effect score. However, 132 women 
(76.74%) had experienced at least one o f  those OC physical side effects. While 15 women 
who experienced only positive mood change were not included in this sample, about half o f the 
sample o f participants experienced negative mood effects while taking OCs, and more than 
three quarters experienced negative physical side effects.
Correlations between the main variables were also examined, and are given in  Table 4. 
Correlations indicated that women with higher body dissatisfaction also reported more 
dysfunctional eating symptoms. Furthermore, women with more symptoms o f eating 
dysfunction also indicated experiencing a higher number o f  mood and somatic side effects 
when taking OCs. Similarly, correlations indicate that women who are more dissatisfied with 
their bodies also reported experiencing higher numbers o f  OC mood and somatic side effects.
A series o f t-tests were carried out to further examine how participants with and without OC 
side effects differed on body dissatisfaction. Participants who did experience mood side
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Table 3
Means and Standard Deviations fo r  the OC Side Effects and EDI-II Subscales
Scale Current Study Current Study Gam er (1991)
(N = 268) (N = 268) Nonpatient Reference
Mean (SD) EDI-II Scoring Sample (N = 205)
Mean (SD) Mean (SD)
M ood Side Effects 1.58 (2.03) — —
Physical Side Effects 2.02(1.86) — —
Body Dissatisfaction 24.21 (10.56) 9.87 (7.49)* 12.2 (8.3)
Eating Dysfunction 1.65 (0.51) — —
Bulimia 7.47 (5.35) 1.60 (2.59) 1.2 (1.9)
Drive for Thinness 14.42 (8.72) 4.96 (5.57) 5.5 (5.5)
'■ p <  .05.
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Table 4
Intercorrelations Between Eating Disorder Symptom and OC Side Effect Variables
Measure BD EDy MSE PSE
BD — .703** ^16** 241* *
EDy — 244* * .276**
MSE — .447**
PSE —
Note. BD = body dissatisfaction; EDy = eating dysfunction; MSE = number o f oral 
contraceptive mood side effects; PSE = number o f oral contraceptive physical side effects. 
Sample sizes range from 152 to 251.
* * p < . 0 1 .
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effects reported significantly higher body dissatisfaction (M =  26.47, SD = 9.99) than those 
who did not experience mood side effects (M =  22.64, SD = 10.10), t (152) = -2.32,p  = .022. 
There was also a trend indicating that women who experienced physical OC side effects had 
higher body dissatisfaction {M=  24.93, SD  = 10.41) than those who did not (M =  20.85, SD  = 
9.13), t (164) = -2 .\6 ,p  = .032.
Similar t-tests were conducted to examine the relationship between the experience of 
OC side effects and eating dysfunction scores. Participants who had experienced OC-related 
mood effects reported greater eating dysfunction (M =  1.79, SD = 4.64) compared to those who 
experienced no mood effects (M =  1.57, SD  = .490), t (150) = -2.83, p  = .005. Those 
participants who had experienced physical side effects also reported greater eating dysfunction 
{M=  1.72, SD = .498) compared to those who experienced no physical side effects {M ~  1.48, 
SD  = .499), t (162) = -2.78, p  = .006. Therefore, participants who had experienced either mood 
or physical OC side effects reported greater body dissatisfaction and eating dysfunction than 
women without these side effects.
Main Analyses
All standard multiple regressions were performed using SPSS REGRESSION with both 
predictor variables entered at once. A multiple regression was conducted to determine whether 
body dissatisfaction scores could be predicted using the two predictor variables, OC m ood side 
effects and OC physical side effects. The linear combination o f the two predictors was 
significantly related to participants’ body dissatisfaction scores, F  (2, 150) = 5.98, p  = .003, R 
= .27, and accounted for 7% of the variability in body dissatisfaction scores (adjusted = .06). 
Examination o f the predictor variables indicated that neither mood side effects (fi = .15, t =
1.70, sN  = .01, p  = .092) nor physical side effects (B = .17, t = 1.94, sN  = .02, p  = .054) were 
unique predictors of body dissatisfaction, although a trend towards significance was noted for 
the latter. Thus, while the number o f mood and physical side effects were not unique predictors
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o f body dissatisfaction, both types o f oral contraceptive side effects combined to add to the
prediction o f  body dissatisfaction.
A second multiple regression was conducted to determine whether eating dysfunction 
scores could be predicted using the same two predictor variables. The linear combination o f the 
two predictors was significantly related to participants’ eating dysfunction scores, F  (2, 148) = 
8.09, p  < .001, R = .31, and accounted for 10% of the variability in eating dysfunction scores 
(adjusted = .09). Examination o f  the predictor variables indicated that physical side effects 
(B = .23, t = 2.59, sF  = .04, ^  = .01) was a unique predictor o f eating dysfunction. M ood side 
effects did not show a unique contribution, (B == .14 ,t= 1 .56 , 5r ^ = . 0 1 , p  = .122) These results 
indicated that the number o f  OC physical side effects that a woman reports experiencing is 
predictive o f eating dysfunction scores, even after controlling for num ber o f  mood side effects.
Both BMl and lifetime history o f depression are correlated with body dissatisfaction ( r 
= .431, r = .421) and eating dysfunction ( r  = .311, r  = .507), respectively (see Appendix J). 
Given these relationships, it is possible that the prediction o f eating disorder symptoms by  OC 
side effects occurred due to individual differences in BM l or differences in mood or cognitive 
style associated with having been diagnosed with depression. Therefore, a sequential 
regression was performed to examine whether oral contraceptive side effects predicted body 
dissatisfaction above and beyond both BM l and lifetime diagnosis o f depression. BM l and 
lifetime diagnosis o f depression were entered on the first step. Number o f  OC mood side 
effects and number o f OC physical side effect were entered on the second step. After step 1, 
with BMl and depression in the equation, F,nc (2, 143) = 23.36, p  < .001, R = .50, R^ = .25, 
adjusted R^ = .24. Body mass index was a unique predictor (B = .46, t = 6.16, sF  =  .20, p  < 
.001), but history o f depression was not (B = .11, f = 1.43, s F  = .01, p  = .154). After step 2, the 
linear combination o f the OC side effect variables significantly predicted body dissatisfaction 
scores above and beyond differences in BMl and history o f depression, R^ change = .06, F  (2,
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141) = 5.65, p  = .004. All four variables in step two significantly predicted body
dissatisfaction (p < .001) and accounted for 30% o f the variance in scores (adjusted = .28).
Mood side effects (B = .18, t = 2.30, sF  = .03, = .023) was a unique predictor o f body
dissatisfaction but physical side effects was not (B = .09, t = 1.17, 5%= .01, p  = .245). In this
model, the two oral contraceptive side effect scores accounted for 5% (4% adjusted) o f  the
total variance in hody dissatisfaction scores, even after controlling for BM l and lifetime
diagnosis o f depression. In addition, OC mood side effects was a unique predictor o f  body
dissatisfaction.
An identical sequential regression was performed to examine whether oral 
contraceptive side effects predicted eating dysfunction above and beyond both BM l and 
lifetime diagnosis o f  depression. After step 1, with BM l and depression in the equation, Ajnc (2, 
141) = 14.91, p  < .001, R = .42, R^= .18, a d j u s t e d = .16. Body mass index was a unique 
predictor o f eating dysfunction (B = .40, t=  5.\A, sF  = .15, p  = < .001), but history o f  
depression was not (B =.06, t = 0.78, sF  = -.004, p  = .436). After step 2, the linear combination 
o f the two OC side effect variables significantly predicted eating dysfunction scores above and 
beyond BMl and history o f depression, R^ change = .08, F  (2, 139) = 7.01, jo = .001. Overall, 
all four variables significantly predicted eating dysfunction, F„ic (4, 139) = 11.60, p < .01, R = 
.50, R^= .25, adjusted R  ̂= .23. Mood side effects (B = .17, t = 2.02, sF =  .02, p  =  .045) 
showed a trend towards being unique predictor o f  body dissatisfaction over and above both 
BM l and lifetime diagnosis o f depression, as did physical side effects to a lesser extent (B =
.16, t = 1.88, sF  = .02, p  = .063). In this model, the two oral contraceptive side effect scores 
account for 8% (7% adjusted) o f the total variance in eating dysfunction scores, even after 
controlling for BM l and lifetime diagnosis o f depression. In addition, history o f OC m ood side 
effects was a unique predictor o f current eating dysfunction.
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Phase Two; Genes and Eating Disorder Symptoms
Descriptive Data and Preliminary Analyses
Tables 5 through 8 show the allele and genotype frequencies for the estrogen receptor
alpha, estrogen receptor beta, serotonin transporter, and progesterone receptor genes,
respectively. For the TA repeat on the estrogen receptor alpha gene, 15 different alleles were
identified, comprising 180 to 212 base pairs (bp; see Table 5). The frequency and distribution
of alleles was similar to that reported by others (e.g., Westberg et al., 2003). For the CA repeat
on the estrogen receptor beta gene, 14 different alleles were identified, comprising 102 to 130
base pairs (see Table 6). Once again, the frequency and distribution o f alleles was similar to
that reported in other studies (e.g., W estberg et al., 2001).
Examination o f  the 16/17 base pair repeat on the serotonin transporter gene resulted in
the identification o f 4 alleles including 8 , 9 , 1 0  and 12 repeats (see Table 7). The 8 allele
appears to be a newly identified allele which has never before been reported. Other than the 8
allele, allelic frequencies are similar to those reported in the literature (e.g., Ogilvie et al.,
1996). Data from the present study indicates a greater frequency o f the 12/12 genotype and less
o f the 10/12 genotype when compared to most other studies o f the same region (e.g.,
Hranilovic et al., 2003; N i et al., 2006). However, Rees and colleagues (1997) reporter similar
frequencies in their British sample.
Eight alleles were identified for the CA repeat on the progesterone receptor gene,
comprising 262 to 276 base pairs (see Table 8). While there is only one study for comparison,
allelic frequencies appear to be similar to that reported by Tsukamoto and colleagues (1998),
with two consecutive alleles accounting for approximately 80% o f the total frequency.
Due to the hypothesized link between repeat number and gene function (i.e.. Comings,
1999), the genotypes o f  all four genes were examined by creating three groups: women with
two short alleles (S/S), women with two long alleles (L/L), and women with one short and one
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Tdfte5
The TA Repeat on the Estrogen Receptor Alpha Gene; Allele and Genotype Frequencies
Alleles




















L/L 3 0 (3 5 3 1 )
Note. S = < 186 base pairs = short allele; L = > 186 base pairs = long allele.
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Table 6
The CA Repeat on the Estrogen Receptor Beta Gene; Allele and Genotype Frequencies
Alleles
Base Pairs (Repeat Numbers) Frequencies (%)
102(18) 1 (0.47)
104(19) 11 (531)
106(20) 5 (2 3 7 )
108(21) 4(1 .90)
110(22) 24(11.37)













L/L 23 (2 7 3 1 )
Note. S = < 116 base pairs = short allele; L = > 116 base pairs = long allele.
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Table 7
The 16/17 Base Pair Repeat on the Serotonin Transporter Gene;
Allele and Genotype Frequencies











Base Pairs (Repeat Numbers)
Genotypes
Frequency (%)
228/261 (8/10) 1 (0.93)
244/261 (9/10) 3 (2 3 0 )
244/294 (9/12) 1 (0.93)
261/261 (10/10) 26 (24.30)
261/294 (10/12) 27 (25.23)





Note. S = 8 to 10 alleles = short allele; L = 12 alleles = long allele.
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Table 8
The CA Repeat on the Progesterone Receptor Gene; Allele and Genotype Frequencies
Alleles












S/L 1 0 (7 3 7 )
L/L 60 (47.24)
Note. S = < 268 base pairs = short allele; L = > 268 base pairs = long allele.
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long allele (S/L). A median split was used to create the groups for three o f the genes in the
following way; estrogen receptor alpha gene (< 186 bp = short; >186 bp = long), estrogen
receptor beta gene (< 116 bp = short; >116 bp = long), and the progesterone receptor gene (<
268 bp = short; >268 bp = long) . For the serotonin transporter gene, the 8, 9, and 10 alleles
were considered short and the 12 allele was considered long. This grouping is consistent with
the literature that describes functional differences associated with the length o f the allele
(Fiskerstrand et al., 1999; M acKenzie & Quinn, 1999) and is appropriate considering there are
very few cases o f the 8 and 9 alleles.
Data Screening and Assessing MANOVA Assumptions
Multivariate normality was assessed by examining skewness, kurtosis and presence o f 
outliers for body dissatisfaction and eating dysfunction for all three genotype groups (S/S, S/L, 
L/L) for each gene. Normality was judged based on visual examination o f histograms and the 
following criteria: [(skewness = standard error o f  skewness) < 3] and [(kurtosis = standard 
error o f kurtosis) < 3] (Tabachnick & Fidell, 2001). Body dissatisfaction and eating 
dysfunction (square root) were reasonably normally distributed for the three genotypes for each 
gene.
Screening for outliers revealed one univariate outlier in the distribution o f  eating 
dysfunction scores for the progesterone receptor genotype. Thus, the score for participant #249 
in the L/L group was changed to the next highest value. Following that correction, no further 
univariate outliers were discovered. No multivariate outliers were found using Mahalanohis 
distance (p < .001 criterion). Fewer than 5% of subjects had missing data on either the body 
dissatisfaction or eating dysfunction variable.
Before undertaking analyses to test the m ain hypotheses, the data were examined to 
ensure that assumptions o f MANOVA were met based on criteria described by Tabachnick and 
Fidell (2001). The correlation between the two dependent variables, body dissatisfaction and
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eating dysfunction, was high, r (255) = .105, p  < .000. However, the correlation is not so high
as to violate assumptions o f multicollinearity and singularity. A scatterplot o f body
dissatisfaction and square root o f eating dysfunction indicated that linearity o f  the dependent
variables was adequate. Sample sizes were unequal due to naturally occurring differences in
the frequencies o f genotypes, however SPSS MANOVA controls for such differences. B ox’s
M tests for homogeneity o f variance-covariance matrices were not significant for the
MANOVAs, thus confirming adequate homogeneity o f variance-covariance matrices for all
analyses.
The following decisions regarding data analyses were made. For each o f the four sets o f 
main analyses, MANOVAs were performed using an alpha level o f .025. Significant 
MANOVAs were followed up by univariate ANOVAs. W ilks’ lambda was used for evaluating 
multivariate significance in all analyses. Tukey’s Honestly Significant Difference (HSD) post 
hoc comparisons were done on the significant effects with an alpha level o f .025.
Assessing fo r  Group Equivalency
For each analysis, genotype groups (S/S, S/L, L/L) were examined for equivalency in 
terms o f age and BML The estrogen receptor alpha, serotonin transporter, and progesterone 
receptor genotype groups did not show differences in BMl or age (all p  > .05). However, while 
age did not differ between groups for the estrogen receptor beta gene, F{2, 80) = 1.312,/? = 
.275, the groups differed in BMl, F{2, 79) = 3.434,/? = .037, with the S/L group (M= 24.81, SD  
= 6.17), being larger than the S/S group (M= 20.89, SD  = 2.85). Post hoc Bonferroni tests 
indicated that the S/S estrogen receptor beta genotype group had a significantly lower mean 
BMl when compared with the S/L group (/? = .034). The S/L and L/L groups did not differ in 
BM l (/? = .742). Given that phase one analyses indicated positive correlations between BM l 
and both dependent variables, BM l was used as a covariate for the MANOVA conducted with 
the estrogen receptor beta gene.
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Main Analyses
The means and standard deviations of the body dissatisfaction and eating dysfunction 
scores as a function o f  genotype for the four genes are listed in Table 9.
Estrogen Receptor Alpha Gene. A one-way between-subjects MANOVA was 
performed on two dependent variables: body dissatisfaction and eating dysfunction. The 
independent variable was estrogen receptor alpha genotype (S/S, S/L, and L/L). W ith the use o f 
W ilks’ criterion, a very weak trend towards significance was observed for an effect o f  the 
estrogen receptor alpha genotype on the combined DVs, F  (4, 142) = 1.91, p  = .102, partial 
= .05, power = .58. The body dissatisfaction and eating dysfunction means increased over the 
three genotype groups (see Table 9), indicating that the L allele or the L/L genotype may be 
associated with greater eating dysfunction.
Given the weak trend for the MANOVA, a follow-up one-way ANOVA was performed 
for each o f the two dependent variables. The results indicated that there was not a significant 
effect o f  genotype for body dissatisfaction, R(2, 72) = 1.10,/? = .337, .03, power = .24.
However, there was a strong trend towards a main effect for eating dysfunction F{2, 72) = 
3.39,/? = .039, partial r j ^ =  .09, power = .62. Because o f the strong trend, multiple comparisons 
between groups for eating dysfunction were examined. Post hoc tests showed a trend towards a 
significant difference for groups S/S and L/L, q {df=  72) = -.39,/? = .032. Thus, participants 
with the L/L genotype showed more eating dysfunction than those with the S/S genotype. 
W omen with the S/S and S/L genotypes, q {df=  72) = -.28,/? = .15; and the S/L and L/L 
genotypes, q {df=  72) = .11,/? = .67, did not differ in terms o f eating dysfunction scores. 
Estrogen Receptor Beta Gene. A one-way between-subjects MANGO VA was performed on 
two dependent variables: body dissatisfaction and eating dysfunction. The independent variable 
was estrogen receptor beta genotype (S/S, S/L, and L/L). BM l was entered as a covariate. W ith
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Table 9
Body Dissatisfaction and Eating Dysfunction M eans by Genotype Group





S/S ( n = I 8 ) 21.06(10.22) 1.39(0.44)
S/L ( n = 33) 22.90(10.00) 1.67 (0.50)
L/L (n  = 29) 25.65 (10.97) 1.79 (0.53)
Estrogen Receptor Beta
S/S ( n = 1 4 ) 20.50 (9.93) 1.53 (0.60)
S/L ( n = 41) 25.51 (11.58) 1.71 (0.55)
L/L (n  = 20) 23.90(12.50) 1.74 (0.51)
Serotonin Transporter
S/S ( n = 28) 21.61 (11.63) 1.53 (0.46)
S/L ( n = 27) 21.74(11.34) 1.63 (0.59)
L/L ( n = 42) 25.13 (9.84) 1.72 (0.46)
Progesterone Receptor
S/S ( n = 52) 25.04(10.04) 1.73 (0.50)
S/L ( n = 9) 20.89 (14.59) 1.38(0.47)
L/L ( n = 56) 23.45 (9.83) 1.65 (0.44)
Note. S = short allele, L = long allele.
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the use o f W ilks’ criterion, there was no significant effect o f the estrogen receptor beta
genotype on the combined DVs, F  (4, 134) = 3 5 ,p  = .844, power = .13. Therefore, estrogen
receptor beta genotype appears to have no association with body dissatisfaction or eating
dysfunction.
Serotonin Transporter Gene. Once again, a one-way between-subjects MANOVA was 
performed on the two dependent variables: body dissatisfaction and eating dysfunction. The 
independent variable was serotonin transporter genotype (S/S = short/short, S/L = short/long, 
and L/L = long/long). W ith the use o f  W ilks’ criterion, there was no significant effect o f 
serotonin genotype on the combined DVs, F  (4, 182) = .874,/? = .481, partial = .02, 
power = .28. Thus, body dissatisfaction and eating dysfunction did not differ as a function o f 
serotonin transporter genotype.
Progesterone Receptor Gene. Similar to above, a one-way between-subjects MANOVA 
was performed on the two dependent variables: body dissatisfaction and square root o f  eating 
dysfunction. The independent variable was progesterone receptor genotype (S/S = short/short, 
S/L = short/long, and L/L = long/long). W ith the use o f W ilks’ criterion, there was no 
significant effect o f progesterone receptor genotype on the combined DVs, F  (4, 222) = 1.15,/? 
= .335, partial = .02„ power = .36. Therefore, the three progesterone receptor genotype 
groups did not differ as a function o f body dissatisfaction and eating dysfunction.
Discussion
Summary o f  the Findings fo r  OC Side Effects and Eating Disorder Symptoms 
Results o f the analyses showed support for all four OC-related hypotheses. Both 
correlations and t-tests indicated that women with a history o f OC-related mood or physical 
side effects had higher levels o f body dissatisfaction and eating dysfunction. The results o f the 
multiple regressions reinforced these findings. The linear combination o f the predictor 
variables (OC mood and physical side effects) significantly predicted body dissatisfaction
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The Involvement o f 64 
scores. A trend towards significance was observed for OC physical side effects as a unique
predictor. Thus, women with a history o f experiencing somatic side effects such as
nausea/vomiting, weight gain, fatigue, headaches, and heavier periods while taking OCs have
higher current levels o f body dissatisfaction. Similarly, the linear combination o f  the OC side
effect predictor variables also significantly predicted eating dysfunction scores. Again,
physical OC side effects was a unique predictor o f eating dysfunction scores. Even after
controlling for individual differences in BMl or history o f depression, OC-related mood and
somatic side effects still significantly predicted eating disorder symptomatology.
Oral Contraceptive Side Effects are Found in Women 
with Higher Body Dissatisfaction and Eating Dysfunction 
The results suggest that women with a history o f  OC side effects have higher body 
dissatisfaction and eating dysfunction than women without such a history. The study’s method 
does not allow for any conclusions about cause-and-effect. However, before this finding is 
accepted as a true relationship it is important to rule out potential confounding factors. First, it 
is possible that overlapping item content o f the scales could explain the relationships. That is, 
women with greater eating disorder symptoms might appear to experience more physical OC 
side effects simply because both scales share similar physical symptoms. Similarly, women 
with greater eating disorder symptoms may appear to experience more mood OC side effects 
because the EDI-II scales and the mood side effect items contain similar affective content, (i.e., 
feeling depressed and feeling depressed about one’s body). In order to examine this possibility, 
correlations between individual items on the EDI-II and number o f  mood and physical side 
effects were examined (see Appendix H) to see if  affective items were primarily correlated 
with number o f mood side effects, and if  somatic items were primarily correlated w ith number 
of physical side effects. A variety o f types o f EDI-II items (somatic, affective, cognitive) were 
correlated with number o f mood and number o f physical OC side effects, and some EDI-II
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items correlated with both types o f side effects. Therefore, it seems unlikely that the
relationship between eating disorder symptoms and OC side effects is due solely to item
content overlap.
Given the previously described results, it appears that there is a relationship between a 
history o f oral contraceptive side effects and current eating disorder symptomatology. There 
are a number o f reasons why these two constructs might be related. Five o f these possible 
explanations for the relationships include: a) greater somatic sensitivity, b) indirect 
pharmacological effects, c) altered physiology due to disordered eating, d) personality effects, 
and e) direct pharmacological effects and hormonal sensitivity. Each o f  these potential 
explanations is discussed below.
Greater Somatic Sensitivity
There are two possible ways in which greater somatic sensitivity might account for the 
relationship between OC side effects and eating disorder symptoms. The first possible way 
somatic sensitivity might explain the link between OC side effects and eating disorder 
symptoms is that women with greater somatic sensitivity may be more likely to recognize 
physical changes in their body (i.e., weight gain) due to OCs. This greater awareness o f  side 
effects such as weight gain could increase their likelihood o f feeling dissatisfied w ith their 
bodies and engaging in disordered eating compared to women who are less aware o f OC- 
related weight gain. Therefore, in this case, the experience o f OC side effects causes greater 
body dissatisfaction and eating dysfunction.
The second possible way somatic sensitivity might explain the relationship between OC 
side effects and eating disorder symptoms is that women with greater somatic sensitivity may 
be more likely to recognize OC side effects and in addition may also be more likely to 
recognize other changes in their physical body unrelated to OCs (i.e., cyclical weight gain 
during the menstrual cycle). If these women are more conscious o f  bodily changes they may be
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at risk for greater body dissatisfaction and eating dysfunction due to their tendency to focus on
their body. Thus, in this case women with greater somatic sensitivity would be more likely to
report experiencing OC side effects and greater eating disorder symptoms, though not because
of a causal link between these constructs.
The eating disorder literature provides some information regarding the somatic 
sensitivity explanation. Poor interoceptive awareness is often reported as a personality 
correlate o f anorexia (see review by Lilenfeld et ah, 2006). Gamer (1991) defines interoceptive 
awareness as confusion regarding emotional states and physical symptoms o f hunger and 
satiety. One study o f a sample o f eating disorder patients found that eating disorder symptoms 
were negatively correlated with awareness o f bodily signals in general, beyond hunger and 
satiety (Spoor et ah, 2005). Thus, the literature does not support this greater somatic sensitivity 
hypothesis and seems to suggest that people with greater eating disorder symptomatology 
actually have less somatic sensitivity.
The possibility that greater sensitivity to OC side effects such as weight gain causes 
greater body dissatisfaction and eating dysfunction can be explored using data from the present 
study. However, when weight gain was removed from the OC physical side effect score, body 
dissatisfaction was still significantly predicted by number o f OC side effects, even after 
controlling for BMl and history o f depression, change = .05, F  (2, 141) = 5.09, p  = .007. 
The entire model accounted for 30% o f the variance in body dissatisfaction (adjusted R^ = .28). 
Similarly, OC side effects (omitting weight gain) significantly predicted eating dysfunction 
after controlling for BM l and history o f depression, F  (2, 139) = 5.52, p  = .005, R^ change = 
.06. Thus, OC side effects are still significantly related to eating disorder symptoms beyond the 
contribution o f OC-related weight gain. This suggests that being aware o f OC-related weight 
gain cannot fully explain the relationship between OC side effects and eating disorder 
symptoms. That conclusion also rules out another explanation for the relationship between OC
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side effects and eating disorder symptomatology; the possibility that women with greater
eating disorder symptoms weigh themselves more often and are thus more likely to be aware o f
and indicate weight gain as an OC side effect.
In sum, greater somatic sensitivity in some women may cause them to be more aware 
o f OC-related physical changes such as weight gain and subsequently experience m ore eating 
disorder symptoms. Alternately, women w ith greater somatic sensitivity may be m ore aware o f  
both OC-related physical side effects and other physical changes in the body such as weight 
gain, and therefore report more OC side effects and greater eating disorder symptoms.
However, eating disorder literature does not support these explanations given that women with 
greater eating disorder symptomatology appear to be less somatically sensitive. Furthermore, 
data from the present study shows that awareness o f OC-related weight gain does not fully 
account for the relationship between OC side effects and both body dissatisfaction and eating 
dysfunction. Thus, there is not strong support for the somatic sensitivity explanation o f the 
findings.
Altered Physiology Due to Disordered Eating
Another possible explanation for the findings is that disordered eating, such as a 
restricted diet or bingeing and purging, alters female physiology such that when these women 
subsequently take OCs, they experience more physical and mood side effects. Chronic dieting 
is known to have a number o f effects on the female body; including poor nutritional status due 
to reduced macro and micro nutrient intake, decreased bone density, metabolic changes and 
menstrual dysfunction (see review by Manore, 1996). Frequent bingeing and purging can 
produce decreased blood acidity, along with fluid and electrolyte abnormalities that include 
plasma deficiencies in potassium, sodium and chlorine (American Psychiatric Association,
2000). Thus, a number o f  bodily functions can be disturbed as a result o f  chronic dieting and 
binge/purge behaviour.
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The possibility that the relationship between OC side effects and eating disorder
symptoms is due to physiological complications o f  dieting and binge/purge behaviour should 
therefore be tested. To factor out complications of bulimic behaviours, the relationship 
between body dissatisfaction and OC side effects was examined, controlling for scores on the 
Bulimia subscale o f  the EDI-II. Items on the Bulimia subscale focus on binge and purge 
behaviour (e.g., I stuff m yself with food, I have gone on eating binges where I felt that I could 
not stop). A sequential multiple regression was performed with bulim ia scores entered in the 
first step, and w ith number o f OC mood and physical side effects as the predictors o f  body 
dissatisfaction. OC side effects showed a trend towards significant prediction o f body 
dissatisfaction above and beyond the effects o f reported bulimic behaviour, change = .04, F  
(2, 147) = 3.47, p  = .034. Therefore, even when individual differences in hinge and purge 
behaviours have been controlled, OC side effects still show a trend towards significant 
prediction o f  body dissatisfaction.
Given that OC side effects predict body dissatisfaction even after controlling for 
bingeing and purging behaviour, it is still possible that the relationship between eating disorder 
symptoms and OC side effects might be partly explained by altered physiology due to 
restrictive eating. However, it is worth noting that studies have indicated that some 
physiological differences in women with eating disorders, such as altered serotonin activity in 
restricting-type anorexics, are not due to malnutrition or low BM l (Frank et ah, 2000). 
Therefore, it is possible that pre-existing physiological differences are present between 
individuals with disordered eating and those without. In addition, the results o f the sequential 
regression do not provide support for the hypothesis that the connection between OC side 
effects and eating disorder symptoms is related to altered physiology due to disordered eating 
(i.e., bingeing and purging).
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Indirect Pharmacological Effects
Individuals who use OCs and experience negative side effects may be at increased risk 
o f  experiencing eating disorder symptoms due to the indirect effects o f hormones on the 
physical body. For example, an increase in weight due to OCs may lead to greater eating 
disorder symptoms because a person has gained weight and begins to experience more 
dissatisfaction in their body, and subsequently engages in more disordered eating. Similarly, 
negative mood caused by OC use may increase eating disorder symptom risk because a person 
is feeling more depressed and so evaluates their body in a more negative light.
In order to examine this indirect pharmacological effect hypothesis further, the 
relationship between the OC side effect weight gain and the eating disorder variables were 
examined. The OC physical side effect o f  weight gain had significant correlations with a large 
number o f  EDI-II items (14 items). W eight gain was also the most highly correlated OC 
physical side effect with eating dysfunction, r = .295 (see Appendix I). Thus, the OC side 
effect o f weight gain appears to be strongly related to the eating disorder symptom variables. 
However, as previously described, when weight gain was removed from the OC physical side 
effect score, body dissatisfaction and eating dysfunction were still significantly predicted by 
num ber o f OC side effects, even after controlling for BM l and history o f  depression. Thus, OC 
side effects remain significantly related to eating disorder symptoms when OC-related weight 
gain is excluded from the score. This suggests that OC-related weight gain cannot fully account 
for the relationships between eating disorder symptoms and OC side effects.
If  the relationship between OC side effects and eating disorder symptomatology was 
due solely to weight gain, one would expect other OC symptoms that increase body size to 
heighten body dissatisfaction and subsequently increase eating dysfunction. However, OC side 
effects such as increased breast size and swelling o f the abdomen were not significantly 
correlated with body dissatisfaction or eating dysfunction (see Appendix I). In sum, there is
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evidence that women who have experienced the OC side effect o f weight gain also have
increased body dissatisfaction and eating dysfunction. However, this relationship cannot
account for the entire relationship between eating disorder symptoms and OC side effects.
To examine whether OC-related negative mood effects might account for the 
relationship between OC side effects and eating disorder symptoms, correlations between the 
OC side effect o f depression and eating disorder symptoms were examined. OC-mediated 
depression was correlated with body dissatisfaction, r  = .176, and eating dysfunction, r  = .190 
(see Appendix I), providing support for the mood aspect o f the indirect pharmacological effects 
explanation. However, when depression was removed from the OC mood side effects variable 
and a sequential regression was conducted controlling for BMl, current negative affect, and 
current depression scores, OC side effects still significantly predicted body dissatisfaction 
scores, F (2 , 135) = 4.47, p  = .013, change = .04. This model accounted for 41% o f the 
variability in body dissatisfaction scores {R^ = .41, adjusted R^ = .39). An identical sequential 
regression was conducted in which OC side effects (omitting depression) significantly 
predicted eating dysfunction after controlling for BM l, current negative affect, and current 
depression scores, F (2, 133) = 3.87, p  = .023, R^ change = .04. Thus, the OC side effect o f 
depression cannot fully account for the link between OC side effects and eating disorder 
symptoms.
In review, some initial support is found for the indirect pharmacological effects 
explanation o f the relationship between OC side effects and eating disorder symptoms. That is, 
OC side effects o f weight gain and depression were both significantly correlated with body 
dissatisfaction and eating dysfunction. Thus, these OC side effects could cause w om en to feel 
badly about their bodies and evaluate themselves in a negative light, and consequently increase 
their dysfunctional eating. However, when these OC side effects were removed from the OC 
mood and physical side effect scores, the remaining side effects still significantly predicted
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body dissatisfaction and eating dysfunction. Thus, it appears that indirect pharmacological
effects do not strongly influence the relationship between OC side effects and eating disorder
symptomatology.
Personality Effects
W omen who report experiencing greater body dissatisfaction, eating dysfunction, and 
greater OC side effects may be more neurotic. Neuroticism can be described as a ‘negativity’ 
factor (biological or environmental) which drives people to indicate that they have experienced 
any sort o f negative experience (Costa & McCrae, 1992). Thus, the relationship between eating 
disorder symptoms and OC side effects might occur solely because people with a neurotic 
personality type endorse more o f both types o f symptoms.
To explore this possible explanation for the relationship between OC side effects and 
eating disorder symptoms, correlations between scores o f  the neuroticism scale o f  the NEO-PI- 
R (Costa & McCrae, 1992) and the four main variables o f  interest show that neuroticism is 
significantly positively related to both body dissatisfaction and eating dysfunction (see 
Appendix J). Neuroticism is also significantly positively correlated with number o f  OC mood 
side effects, but not physical side effects. Thus, neuroticism does not seem to drive greater 
reporting o f OC physical side effects.
The relationship between the eating disorder symptom and OC variables was examined 
after controlling for neuroticism, BMl, current negative affect, and current depression scores. 
W ith all o f these variables partialled out, OC side effects showed a trend for significant 
prediction o f body dissatisfaction, F  (2, 121) = 2.58, p  = .080, change = .02. W ith all seven 
variables in the model, 49% o f  the variability in body dissatisfaction scores was explained 
(adjusted R^ = .47). In an identical sequential multiple regression, OC side effects significantly 
predicted eating dysfunction, after controlling for neuroticism, BMl, negative affect and 
depression, F  (2, 117) = 3.94, p  = .022, R^ change = .04. The overall model was also
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significant,/? < .001, R = .67, R^ = .45, adjusted R^=  .42. Thus, while neuroticism may play an
important role in the relationship between OC side effects and eating disorder symptoms,
neuroticism cannot completely account for the relationship between these variables.
Given that depression is associated with negative cognitive patterns, it is possible that 
the relationship between eating disorder symptoms and neuroticism is driven by greater 
depressive symptoms in these subjects. Indeed, neuroticism scores are significantly correlated 
with current ratings o f negative affect and depressive symptoms (see Appendix J). However, 
when controlling for negative affect and depressive symptoms there is still a significant 
relationship between neuroticism and both body dissatisfaction (partial r = .356,p  < .001, N  = 
126), and eating dysfunction (partial r  = .345, p  < .001, N =  126). In addition, when 
neuroticism is controlled for, body dissatisfaction is no longer correlated w ith ratings o f 
negative affect (partial r = -.037,/? = .681, N =  127) and depression (partial r  = .102,/? = .251, 
N =  127). Similarly, when neuroticism is controlled, eating dysfunction is no longer correlated 
with negative affect (partial r  = -.154,/? = .081, N =  127) and depression (partial r = .133,/? = 
.134, A  = 127). Thus, neuroticism appears to drive the reporting o f negative affect and 
depression, and play a role in eating disorder symptoms.
While the link between neuroticism and eating disorder symptoms may he 
environmental (e.g., both could be due to fam ily communication styles), the link between these 
two constructs may also be biological. As previously mentioned, neuroticism has been linked 
with the estrogen receptor alpha gene (W estberg et ah, 2003), the same gene that was linked 
with eating dysfunction in the present study. A hormonal association between eating disorder 
symptoms and neuroticism may exist and this relationship could be genetically mediated, 
possibly by the estrogen receptor alpha gene. Evidence that neuroticism may have a biological 
cause exists in the correlations between neuroticism and the following: BM l (r = . \5 6 ,p  =
.017, N =  235), age o f menarche (r = -.183, p  = .005, N =  238), and perhaps, rating o f  negative
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mood symptoms prior to menstruation (PMS; r  = ,381,/? < .001, N  = 235). Thus, neuroticism 
might be associated with biological states and thus be related to body dissatisfaction, eating 
dysfunction, and OC side effects via hormonal routes.
If neuroticism is influenced by hormones, individuals who report greater OC side 
effects do not simply report greater body dissatisfaction and eating dysfunction because o f  a 
tendency to endorse any negative experience. These individuals may actually experience more 
o f all types o f these symptoms and more neuroticism because o f some sort o f hormonal 
difference, possibly a greater sensitivity to hormone levels. In sum, neuroticism is related to the 
reporting o f eating disorder symptoms, hut does not fully account for the relationship between 
eating disorder symptomatology and OC side effects. Furthermore, it appears possible that 
hormonal differences underlie neuroticism, eating disorder symptoms, and OC side effects. 
Direct Pharmacological Effects and Hormonal Sensitivity
Individuals who use OCs and experience adverse side effects may also experience 
greater eating disorder symptoms due to a direct pharmacological effect o f OCs. M ore 
specifically, the pharmacological components o f OCs (i.e., estrogen and progesterone) may 
cause both OC side effects and eating disorder symptoms. There are two possible direct 
pharmacological effects explanations for the current finding. One potential direct 
pharmacological effect explanation is that women who experience greater OC side effects and 
greater eating disorder symptoms are more sensitive to the exogenous hormones that compose 
OCs, and taking OCs leads to both side effects and other changes that increase eating disorder 
symptoms. This suggests that women who use OCs are at greater risk for eating disorder 
symptoms after OC use than before. The implication o f this hypothesis is that women who use 
OCs and experience negative mood or physical side effects are at greater risk for eating 
disorders.
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While few relevant studies have been conducted, there is evidence that exogenous
progesterone increases appetite (Reddy & Kulkami, 1998) and that both exogenous estrogen 
and progesterone alter mood in women (Freeman, 1993; Rubinow et ah, 1998). Thus, some 
women may be at increased risk o f eating disorder symptoms after using OCs. In the present 
study, the OC side effects ‘more irritable’, ‘weight gain’ and ‘headaches’ were all correlated 
with body dissatisfaction and eating dysfunction (see Appendix I). Increased irritability, weight 
gain, and headaches are believed to be symptoms of either excess estrogen or lack o f 
progesterone in OC users (see review by Dickey, 2000). Thus, OC users may experience an 
imbalance o f hormones that could also impact their level o f eating disorder symptoms. W hile 
no conclusions can be drawn at this point, it is possible that exogenous hormones play a role in 
the relationship between greater eating disorder symptoms and greater OC side effects.
Another possible direct pharmacological effect explanation for the relationship between 
eating disorder symptoms and OC side effects is that some women are sensitive to both 
exogenous and endogenous hormones. Thus, women who are sensitive to hormones may 
experience OC side effects due to this hormonal sensitivity and may also experience eating 
disorder symptoms due to this hormonal sensitivity. There is evidence that eating disorder 
symptoms are related to endogenous hormone levels. For example, eating disorder symptom 
severity fluctuates across the menstrual cycle (Altabe & Thompson, 1990; Gladis & W alsh 
1987), increased circulating levels o f estrogen correlate w ith eating dysfunction (Klump et ah, 
2006), and there are connections between appetite and feeding and both estrogen and 
progesterone (see review by Eckel, 2004; Giannini et ak, 1985). Thus, levels o f endogenous 
hormones may also have an im pact on eating disorder symptomatology and women who are 
sensitive to hormones may be m ore likely to develop eating disorder symptoms in general, and 
more likely to experience side effects when taking OCs.
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Evidence o f a link between endogenous hormones and both body dissatisfaction and 
eating dysfunction in this study comes from significant correlations between negative mood 
prior to menstruation (PMS) and the eating disorder variables. W omen who experienced more 
(PMS) also experienced significantly higher body dissatisfaction, t (254) = 2 A l , p  = .014, and 
eating dysfunction, t (246) = 3 .25 ,p  = .002. As women with more PMS symptoms may be 
more sensitive to the fluctuations in hormones that occur just prior to menstruation (see review 
by Sundstrom Poromaa et al., 2003), greater eating disorder symptoms may be another 
symptom of sensitivity to hormones. Thus, there is some evidence that eating disorder 
symptomatology is linked to endogenous hormone levels and/or sensitivity to them.
Evidence from the literature and from the findings in the current study provide some 
support for the possibility o f a direct pharmacological effect o f  OCs on eating disorder 
symptoms. W omen who experience a greater number o f OC side effects and eating disorder 
symptoms may be specially sensitive to endogenous and exogenous hormones. One 
implication o f the sensitivity to endogenous/exogenous hypothesis is that the risk o f  eating 
disorders may increase in populations after taking the OC pill. In addition, this hypothesis 
suggests that women who have a higher level o f eating disorder symptomatology are at greater 
risk o f experiencing negative OC side effects.
S u m m a r y  o f  t h e  F i v e  P o s s i b l e  E x p l a n a t i o n s
Five possible explanations for the relationship between eating disorder symptoms and 
oral contraceptive side effects were proposed. First, greater somatic sensitivity could cause 
women to more readily notice OC side effects and to also experience greater eating disorder 
symptoms, either as a result o f OC physical side effects or due to greater bodily awareness in 
general. The literature, as well as the finding that even without weight gain, OC side effects 
could still predict eating disorder symptoms, did not support this explanation. The second 
possible explanation stated that altered physiology due to disordered eating was hypothesized
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to increase OC users’ mood and physical side effects. This hypothesis was not supported based
on evidence that OC side effects still predicted body dissatisfaction scores when bulimia
behaviours were controlled. However, the physical effects o f  a restrictive diet could still be o f
importance to the relationship.
Third, the indirect pharmacological hypothesis was examined. This hypothesis states 
that OC mood and physical side effects cause women to evaluate their bodies more negatively 
and subsequently increase their disordered eating. There was some support for this explanation. 
However, OC symptoms like weight gain, negative affect and depression could not completely 
explain the relationship between OC side effects and eating disorder symptoms. The fourth 
explanation proposed that a neurotic personality trait caused women to endorse both greater 
eating disorder symptoms and more oral contraceptive side effects. W hile neuroticism was 
related to eating disorder symptoms and seemed to be implicated in the relationship between 
eating disorder symptoms and OC side effects, the possibility o f  a common biological basis for 
all variables could not be rejected.
The final explanation stated that direct pharmacological effects o f OCs cause both 
greater OC side effects and greater eating disorder symptoms due to a sensitivity to exogenous 
or both exogenous and endogenous hormones. Evidence that eating disorder symptoms are 
related to endogenous hormones levels and/or sensitivity to endogenous hormones provides 
support for this hypothesis (Altabe & Thompson, 1990; Gladis & W alsh 1987; Klump et al., 
2006). There is also a small amount o f evidence that exogenous hormones are related to 
feeding, appetite and mood (Freeman, 1993; Reddy & Kulkami, 1998).
Thus, the present finding that number o f  oral contraceptive side effects predicts severity 
o f body dissatisfaction and eating dysfunction has a variety o f  possible explanations. The 
relationship may be partly due to indirect pharmacological effects, altered physiology, and a 
neurotic personality style. An underlying hormonal basis for all o f these constructs is possible.
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based on correlations with items that appear to measure differences in hormonal functioning. 
Finally, a direct pharmacological effects o f OCs on eating disorder symptoms remains a 
possibility and seems plausible based on results o f  previous studies.
E x a m i n a t i o n  o f  t h e  F i n d i n g s  f o r  G e n e s  a n d  E a t i n g  D i s o r d e r  S y m p t o m s
The results do not support any o f the four hypotheses for the genetic portion o f  the 
study. In the case o f the estrogen receptor alpha gene it was hypothesized that the short (S/S) 
genotype would be associated with greater eating disorder symptoms. However, when 
compared with the S/S genotype, the long (L/L) genotype showed a trend towards a significant 
association with greater eating dysfunction. The one study that had examined the TA 
polymorphism on the estrogen receptor alpha gene did not find any association between the 
gene and anorexia (Eastwood et ah, 2002). The difference in results may be explained by the 
alternate approach taken in the present study o f  examining the range o f symptoms in a non- 
clinical sample rather than examining absence/presence o f an eating disorder (i.e., comparing 
continuous scores versus dichotomously classified groups).
It is not particularly surprising that positive results were found for the long alleles 
versus the short alleles, as hypothesized. There were no prior eating disorder studies on this 
gene with significant results on which to base a hypothesis, nor was there any published 
evidence o f  functional differences between short and long alleles o f the estrogen receptor alpha 
gene. In the study by Westberg and colleagues (2003) shorter alleles were associated with 
higher neuroticism, and given the link between eating disorder symptomatology and 
neuroticism, it was thought that shorter alleles should then also correspond with greater eating 
disorder symptoms. However, the results o f the W estberg et al. study may not be directly 
comparable to the present study given that it was conducted on a Swedish sample and 
personality factors as well as allelic frequencies can vary by ethnicity.
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Contrary to the hypothesis, no association was found between the CA polym orphism on
the estrogen receptor beta gene and eating disorder symptoms. Some positive associations 
between other polymorphic areas on this gene and eating disorders had been found in the past 
(Eastwood et ah, 2002; Nilsson et ah, 2004), however, not in the present study. Nevertheless, 
an association was found between the estrogen receptor beta gene and BMI. Participants with 
the S/L genotype had a significantly higher mean BMI when compared to those with the S/S 
genotype. These findings indicate that a recessive S/S model o f inheritance on the estrogen 
receptor beta gene m ay predispose one to a lower BMI.
This discovery on the estrogen receptor beta gene also fits with the finding that the 
estrogen receptor beta is involved in the anorectic action o f estrogen (Liang et ah, 2002). 
W om en with the S/L genotype m ay have different expression o f the estrogen receptor beta, 
leading to greater BMI. The study by Takeo and colleagues (2005) provides support for this 
hypothesis. They found that women with certain estrogen receptor beta genotypes had 
significantly more negative mood and physical symptoms during the premenstrual period, and 
during menopause. Both the premenstrual period and menopause are associated w ith low 
estrogen levels (Arpels, 1996). According to Liang and colleagues (2002), decreased levels o f 
estrogen are also associated with obesity. Thus, women with the S/L genotype m ay have lower 
estrogen levels or an alteration in estrogen sensitivity which leads them to have greater BMIs.
Despite promising connections between short alleles o f  the polymorphism on the 2""̂  
intron o f  the serotonin transporter gene and bulimia (Lauzurica et ah, 2003), depression 
(Ogilvie et ah, 1996), suicide (Jemej et ah, 2004), and borderline personality disorder (Ni et ah, 
2006), there was no association found between genotype and eating disorder symptoms for this 
region. It is possible that the connection between the shorter alleles and less serotonin activity 
m ay be less relevant to non-clinical populations, or alternately, to a predominantly Caucasian, 
Canadian sample. Similarly, despite solid theoretical reasons to suspect a role for the
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progesterone receptor gene in eating disorder symptoms, once again no associations were
found. This is an interesting result regardless, given that this is one o f  the first studies to
examine the polymorphism on the progesterone receptor gene.
S t r e n g t h s  a n d  L i m i t a t i o n s  o f  t h i s  S t u d y
The unique approach o f  this study, being the first to examine the role o f hormones in 
eating disorder symptoms by investigating the interaction o f oral contraceptive side effects and 
eating disorder symptoms, provides a new way o f addressing this complex research question. 
This design also offers much-needed information about potential oral contraceptive side effects 
and complications. By examining eating disorder symptoms in a non-clinical sample it allows 
the results to be more widely applicable, and once again is an approach different from most 
studies and thus might provide unique information not found in research that examines clinical 
populations. According to Moffitt, Caspi, and Rutter (2006) this is a preferred method for 
studies searching for candidate genes because endophenotypes are believed to have simpler 
genetic foundations than disorders. More practically speaking, the use o f a large screening 
questionnaire provided many options for testing hypotheses to better understand findings. The 
ability to test hypotheses was important, given the exploratory nature o f this study and the 
entanglement o f biology, cognition, emotion and personality with the constructs o f  interest.
While oral contraceptive users with negative mood change and no mood change were 
examined in this study, users with only positive mood change were not studied. Examining 
eating disorder symptoms in that small group o f users might provide more information about 
the factors underlying the interaction between oral contraceptive side effects and eating 
disorder symptoms. In addition, this subgroup o f women (those who only experienced positive 
OC mood effects) were not included in the genetic analyses. It is possible that this reduced the 
pow er o f the study’s design as some extreme alleles (i.e., particularly short or long) m ay have 
been underrepresented. Similarly, the power o f the design m ay also have been slightly reduced
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if  this subgroup o f women has particularly low or high body dissatisfaction or eating
dysfunction.
This study was also limited in its ability to test some o f the potential explanations for 
the findings. Although the questionnaire provided some information about hormonal sensitivity 
such as premenstrual symptoms and age o f menarche, the items did not provide enough 
information from which to draw conclusions. Items to test altered physiology due to disordered 
eating, somatic sensitivity, and a yea-saying bias would also have helped further elucidate 
potential confounds in this study’s findings.
A potential limitation o f the genetic portion o f the study was that nine regions o f DNA 
were amplified together in one multiplex procedure. While this is a cost effective approach, the 
procedure was newly developed and may be less accurate than amplifying each region on its 
own. To ensure the accuracy o f the repeat numbers in the present study, the regions will be 
sequenced in some samples in order to confirm the results. Another possible limitation lies in 
the study’s design o f  examining direct gene associations with psychopathology. M offitt and 
colleagues (2006) suggest that searching for genes that interact with particular environmental 
factors to produce psychopathology may be a more fruitful approach.
F u t u r e  D i r e c t i o n s  f o r  R e s e a r c h
Future steps in this line o f  research will be to first replicate the findings o f  the present 
study, and then to examine the possible explanations for the relationship found between 
number o f oral contraceptive side effects and greater eating disorder symptomatology. 
Longitudinal studies that examine eating disorder symptoms before, during, and after oral 
contraceptive use could provide further information on the validity o f the indirect and direct 
pharmacological hypotheses, and the somatic sensitivity hypothesis. Studying a hormonal 
connection to neuroticism will also help clarify the nature o f the relationship between oral 
contraceptive mood side effects and eating disorder symptoms. Altered physiology as a result
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o f dysfunctional eating behaviours should also be examined for a link with increased OC side
effects. Measuring changes in circulating hormone levels and examining sensitivity to
hormones could also provide helpful information on the role o f estrogen and progesterone in
the connection between eating disorder symptoms and OC side effects. As mentioned
previously, looking at women who only experience positive mood side effects from oral
contraceptives m ay also help clarify results.
Next steps from the genetic portion o f the study will involve replicating the positive 
associations found between eating dysfunction and the estrogen receptor alpha gene, and BMI 
and the estrogen receptor beta gene with larger and different samples. Information from 
hormonal assays and other hormonal markers such as 2"^ to digit ratio, which is considered 
a robust measure o f  prenatal androgen effects (Klump et al., 2006), m ay add to the findings. In 
addition, the inclusion o f a clinical group when testing the eating dysfunction/estrogen receptor 
alpha gene results would ensure that a wider range o f  eating dysfunction scores are available to 
increase the power o f  the study. Finally, examining the interaction between particular genes 
and environmental factors (e.g., OC use, media exposure, family dynamics) and their effects on 
eating disorder symptoms will be an important step.
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Sex (Circle your answer): m ale female
Please check the box that best describes the highest level of education that you 
have completed:
[ ] some elementary 
[ ] completed grade 8
[ ] some high school
4. Today’s date:
[ ] completed high school [ ] some university
[ ] some college [ ] completed a university
degree
[ ] completed college [ ] some graduate studies
[ ] completed a graduate 
degree







(feet & inches) or 
_ (pounds) o r _____
(cm)
(kg)
Check the box that best describes your current relationship status:
[ ] married or living with partner 
[ ] no partner (single)
[ ] casually dating
[ ] one partner, but living apart 
[ ] more than one partner 
[ ] o ther:____________________
If you are currently in a steady relationship, how long have you and your partner 
been together (in years and m onths)?______ years a n d _______ months.
If you are currently in a steady relationship, rate your happiness/satisfaction with 





2 3 4 5 6 7
10. a. W ere you raised in Thunder Bay? (circle one) YES NO Part o f the Time
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b. W ere you raised in Northwestern Ontario? (circle one) YES NO Part o f  the 
Time
c. If  you were not raised in Northwestern Ontario, was the city/town that you grew 
up in larger in population than Thunder Bay? (circle one) YES NO Same Size
d. Are your biological parents together (married or in a relationship)? (circle one)
YES NO
11. Are you currently taking any medication? (circle one) YES NO
If YES, what medications are you taking? (please list)
12. Please list any medical or psychological conditions that you have been diagnosed 
with (e.g. hypothyroidism, depression, asthma, cancer, diabetes, etc.)
13. Have you ever been diagnosed with or treated for depression? (circle your answer)
YES NO MAYBE




15. Have you ever been diagnosed or treated for an eating disorder? (circle your answer).
YES NO MAYBE
16. Do you think any o f  your relatives (i.e. parents, siblings, children, grandparents) have 
had any mental health problems (i.e. depression, anxiety, schizophrenia, alcoholism, 
eating disorders)? (circle your answer) YES NO
MAYBE
17. For each o f the following, please check the box if  you think that one o f your biological 
relatives has been diagnosed with or treated for this psychological problem. Also, on 
the line beside each mental health problem, please indicate the relationship o f  the family 
member(s) to you (e.g., mother, father, sister, grandmother, uncle).
] D epression__________  [ ] Eating D isorder________________
] Personality D isorder______________  [ ] A lcoholism _______________
] Schizophrenia________________ [ ] Drug A buse________________
] Anxiety D isorder________________ [ ] O ther:________________
] Bipolar Disorder/Manic D epression_______________
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18. To the best o f your ability, please record your biological parents’ ethnicity and the 
percentage or fraction for each different ethnicity (please leave blank if  you do not 
know the information about your biological parents). If  you are unsure o f  the 
percentages or fractions, sim ply record the ethnicities.
The following two exam ples are possible ethnic percentages. Use them as guidelines to fill in vour
biological m other and father’s ethnicity in (a) and (b) below these examples.
al Father’s Ethnicity 1; Finnish 
Percentage for fractionl: 75%
Father’s E thnicity 3: 
Percentage for fraction):
Father’s E thnicity 2: Aboriginal 
Percentage for fractionl: 25%
Father’s E thnicity 4: 
Percentage for fraction):
b l M other’s E thnicity 1: Irish 
Percentage for fractionl: 1/8
M other’s E thnicity 3: Jamaican 
Percentage for fractionl: 1/8
M other’s Ethnicity 2: French 
Percentage for fractionl: 2/8 or 1/4
M other’s E thnicity 4: Scottish 
Percentage for fractionl: 4/8 or 1/2
a) Father’s Ethnicity:
Ethnicity I :




Percentage (or fraction): 
Ethnicity 4:
Percentage (or fraction):
b) M other’s Ethnicity:
Ethnicity I :




Percentage (or fraction): 
Ethnicity 4:
Percentage (or fraction):
19. Check the box o f the statement that best describes you:
[ ] I feel happiest and most productive in the morning hours o f  the day. 
[ ] I feel happiest and most productive in the evening hours o f  the day. 
[ ] I feel equally happy and productive in the morning and evening.
[ ] I feel that none o f  the above statements apply to me.
20. For each o f  the following, please check the box if  you think that one o f  your 
biological relatives has been diagnosed with or treated for this medieal problem. Also, 
on the line beside each medical problem, please indicate the relationship o f  the family 
member(s) to you (e.g., mother, father, sister, grandmother, uncle).
[ ] Breast C ancer_____________  [ ] Prostate C ancer_____________
[ ] Ovarian C ancer_____________  [ ] Testicular C ancer______________
[ ] Cervical C ancer_____________  [ ] Other Cancer (Please specify):
[ ] A utism ______
[ ] Heart Disease
[ ] Fertility Problem s_____________
[ ] Thyroid Disorder (Specify Type if 
known):_________
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21. This scale consists o f a num ber o f  words that describe different feelings and emotions. 
Read each item and then m ark the appropriate answer in the space next to that word. 
Indicate to what extent to which you have felt this way today. Use the following scale 
to record your answers.
1 2 3 4 5
very slightly a little moderately quite a bit extremely
or not at all
interested_________________________irritable
distressed____________________ ___ alert
. excited  ashamed
. upset ____inspired
strong____________________________nervous
. guilty ___ determined
scared____________________________attentive
, hostile ___ jittery
_ enthusiastic ____active
. proud ____afraid
22. Current and Recent Alcohol Use (W ithin the Past 6 months)____________________________
a) Currently, how often do you normally consume alcohol? Circle the number under the best 
answer.
never once or twice once or twice three to four almost
a month or less a week times a week every day
0 1 2 3 4
b) Currently, what is the average number o f  drinks you have when/if you drink? Circle your 
answer.
none one to three four to seven eight to twelve more than 12
0 1 2 3 4
c) Currently, how often do you wake up in the morning with a “hangover” due to alcohol use 
the previous night?
never one to three times four to eight eight to twelve most mornings
a month or less times a month times a month
0 1 2  3 4
d) W ithin the past six months, how many times have you drunk so much alcohol that you 
vomited? Circle the number under the best answer.
never one to three four to seven eight to twelve more than 12 times
0 1 2  3 4
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e) Currently, how often do you skip meals when you consume alcohol? Circle the number 
under the best answer.
never 25% o f the time 50% o f the 75% of the every time
or less time time 1 drink
0 1 2 3 4
23. Past Use o f Alcohol
a) About how old were you when you first took one or more full drinks o f a lcoho l?________
b) About how old were you when you first becam e intoxicated?__________
c) In the course o f one evening, what is the highest number o f alcoholic drinks that you have 
ever consumed?
_________(# o f  drinks) (1 drink = 1 beer, 1 glass o f wine, or 1.25 ounces o f  liquor)
How many times have you consumed this many drinks (give best estimate)?
d) How many times in your life have you drank so much alcohol that you vomited? (put 0 if  
never and estimate if  unsure o f the exact number) _________
e) How many times in your life has your drinking resulted in you having a seizure or 
convulsions? (put zero if  never)________
f) W hen you were in the following different age groups, how often did you norm ally 
consume alcohol? Circle the number that best describes your frequency o f alcohol use during 
that time period. Please leave blank the age groups that are older than your current age.
Age
Group
never once or twice 
a month or less
once or twice 
a week




7-8 0 1 2 3 4
9-10 0 1 2 3 4
11-12 0 1 2 3 4
13-14 0 1 2 3 4
15-16 0 1 2 3 4
17-18 0 1 2 3 4
19-20 0 1 2 3 4
21-22 0 1 2 3 4
23-24 0 1 2 3 4
25-26 0 1 2 3 4
27-28 0 1 2 3 4
29-30 0 1 2 3 4
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g) W hen you were in the following different age groups, what was the average number of 
drinks you had w hen/if you drank? Circle the number that best describes your typical 
consumption o f  alcohol during that time period (note that 2 = four to seven and 4= more than 
12). Please leave blank the age groups that are older than your current age.
Age none one to three 
Group
four to seven eight to twelve more than 12
7-8 0 1 2 3 4
9-10 0 1 2 3 4
11-12 0 1 2 3 4
13-14 0 1 2 3 4
15-16 0 1 2 3 4
17-18 0 1 2 3 4
19-20 0 1 2 3 4
21-22 0 1 2 3 4
23-24 0 1 2 3 4
25-26 0 1 2 3 4
27-28 0 1 2 3 4
29-30 0 1 2 3 4
h) W hen you were in the following different age groups, how many times did you drink so 
much alcohol that you vomited? Circle the number under the response that best describes 
your typical consumption o f  alcohol during that time period (note that 2 = four to seven and 4= 
more than 12). Please leave blank the age groups that are older than your current age.
Age
Group
never one to three 
times/year
four to seven 
times/year
eight to twelve 
times/year
more than 12 
times/year
7-8 0 1 2 3 4
9-10 0 1 2 3 4
11-12 0 1 2 3 4
13-14 0 1 2 3 4
15-16 0 1 2 3 4
17-18 0 1 2 3 4
19-20 0 1 2 3 4
21-22 0 1 2 3 4
23-24 0 1 2 3 4
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25-26 0 1 2 3 4
27-28 0 1 2 3 4
29-30 0 1 2 3 4
24. OTHER DRUGS
a) W ithin the past six months, how often have you typically used recreational/illegal drugs such 
as marijuana, hash, cocaine, LSD, ecstasy, etc.?
never once or twice 
a month or less 
0 1
once or twice 
a week
2




b) Approximately how many times have you tried ecstasy?
3
times
c) Approximately how many times have you tried magic mushrooms (psilocybin)?_______
times
d) Check the box that best describes your smoking status:
[ ] never smoked [ ] previous casual/social smoker [ ] previous smoker
[ ] previous smoker [ ] current casual/social smoker [ ] current smoker
e) I f  you are a current cigarette smoker, how many cigarettes on average do you smoke per 
d ay ?________
f) If  you have ever been a cigarette smoker, how many years did you smoke for? 
years
25. FAM ILY HISTORY
a) U sing the following scale, select the number that best describes the current and highest 
drinking level o f  your biological parents. If  your parent is deceased, please leave the current 
level o f  drinking blank:
Drinking Levels 
0= I don’t know 
1= nondrinker (abstainer) 
ev er:_____
2= occasional or light social drinker 
3= moderate or average social drinker 
4= frequent or heavy social drinker
ev er:_____
5== problem  drinker 
6= alcoholic
biological mother:
current level o f  drinking:
biological father:
current level o f  drinking:
_, highest level
_, highest level
b) Do you believe that you have a family history o f  alcoholism? (Circle answer) Yes No 
M aybe
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c) Have any o f your four biological grandparents ever been problem drinkers or alcoholics?
(Circle answer): Yes N o M aybe
26. Please answer all of the following questions honestly. For the questions dealing with 
behaviour, write your answers in the blank spaces provided. For the questions dealing 
with thoughts and attitudes, circle the appropriate number on the scales provided.
a) With how many different partners have you had sex (sexual intercourse) w ithin the past 
year? ______
b) How m any different partners do you foresee yourself having sex with during the next five 
years? (Please give a specific, realistic estimate) ______
c) W ith how many different partners have you had sex on one and only one occasion? ______
d) How often do (did) you fantasize about having sex with someone other than your current 
(most recent) dating partner? (Circle one. If you have not been in a dating relationship then 
leave this question blank.)
1. Never
2. Once every two or three months
3. Once a month
4. Once every two weeks
5. Once a week
6. A few times each week
7. Nearly every day
8. At least once a day
e) Sex without love is OK.
I Strongly 1 Strongly
Disagree Agree
1 2 3 4 5 6 7 8 9
f) 1 can imagine m yself being comfortable and enjoying “casual” sex with different partners.
1 Strongly 1 Strongly
Disagree Agree
1 2 3 4 5 6 7 8 9
g) I would have to be closely attached to someone (both emotionally and psychologically) 
before 1 could feel comfortable and fully enjoy having sex with him/her.
1 Strongly 1 Strongly
Disagree Agree
1 2 3 4 5 6 7 8 9
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The Involvement o f 105







i) During the past year, with how many different partners have you had only one occasion of 
sexual contact (e.g., hands to genitals, hands to breasts, oral-genital) that did not include sexual 
intercourse?
27. Rate your sexual orientation on the following scale:
I am only attracted 
to people o f  the 
opposite sex
1 2
I am equally 
attracted to people 
o f  both sexes
5 6
1 am only attracted 
to people o f  the 
same sex as me
9
28. Emotions and Personality
a) The following items ask about your attitudes, feelings, and behaviour. Some o f the
items relate to food or eating. Other items ask about your feelings about yourself.
For each item, decide if  the item is true about you ALWAYS (A), USUALLY (U), 
OFTEN (O), SOMETIMES (S), RARELY (R) or NEVER (N). Circle the letter in the adjacent 
column that corresponds to your rating. For example, i f  your rating for an item is OFTEN, you 
would circle the O for that item.
Respond to all o f the items, making sure that you circle the letter for the rating that is 
true about you. If you need to change an answer, make an “X” though the incorrect letter and 
then circle the correct one.
A = ALWAYS, U = USUALLY, O = OFTEN, S = SOMETIMES, R = RARELY, 
N = NEVER
1. I  eat sweets and carbohydrates without feeling nervous. A U 0 s R N
2. I think that my stomach is too big. A U 0 s R N
3. I  eat when I am upset. A U 0 s R N
4. I  stuff myself with food. A U 0 s R N
5. I  think about dieting. A U 0 s R N
6. I  think that my thighs are too large. A U 0 s R N
7. I  feel extremely guilty after overeating. A U 0 s R N
8. I  think that my stomach is just the right size. A U 0 s R N
9. I am terrified of gaining weight. A U 0 s R N
10. I  feel satisfied with the shape of my body. A U 0 s R N
11. I  exaggerate or magnify the importance of weight. A U 0 s R N
12. I have gone on eating binges where I  felt that I could not stop. A U 0 s R N
13. I  like the shape of my buttocks. A U 0 s R N
14. I  am preoccupied with the desire to be thinner. A U 0 s R N
15. I  think about bingeing (overeating). A U 0 s R N
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16. I think my hips are too big. A U 0 S R N
17. I  eat moderately in front of others and stuff myself when they’ re 
gone.
A U 0 s R N
18. If I  gain a pound I  worry that I will keep gaining. A U 0 s R N
19. I  have the thought of trying to vomit to lose weight. A U 0 s R N
20. I  think that my thighs are just the right size. A U 0 s R N
21. I  think that my buttocks are too large. A U 0 s R N
22. I  eat or drink in secrecy. A U 0 s R N
23. I think that my hips are just the right size. A U 0 s R N
b) Please read each o f the following statements carefully and circle the one answer that best 
corresponds to your agreement or disagreement. Circle “sd” if  the statement is definitely false 
or if  you strongly disagree. Circle “d” if  the statement is mostly false or if  you disagree. 
Circle “a” if  the statement is mostly true or if  you agree. Circle “sa” i f  the statement is 
definitely true or if  you strongly agree. There are no right or wrong answers, and you need 
not be an “expert” to complete this questionnaire. Describe yourself honestly and state your 
opinions as accurately as possible.
SD = strongly disagree, D = disagree, N = neutral, A = agree, SA = strongly agree
1 .1 am not a worrier. sd d n a sa
2 . 1 really like most people I meet. sd d n a sa
3 . 1 often get angry at the way people treat me. sd d n a sa
4 . 1 shy away from crowds o f people. sd d n a sa
5 .1 rarely feel lonely or blue. sd d n a sa
6 . 1 am dominant, forceful, and assertive. sd d n a sa
7. In dealing with other people, I always dread making a 
social blunder.
sd d n a sa
8 . 1 have a leisurely style at work and play. sd d n a sa
9. I rarely overindulge in anything. sd d n a sa
10. I often crave excitement. sd d n a sa
11. I often feel hopeless and want someone else to solve 
my problems.
sd d n a sa
12. I have never literally jumped for joy. sd d n a sa
1 3 .1 am easily frightened. sd d n a sa
14. I don’t get much pleasure from chatting with people. sd d n a sa
15. I ’m  an even-tempered person. sd d n a sa
1 6 .1 like to have a lot o f  people around me. sd d n a sa
17. Sometimes I feel completely worthless. sd d n a sa
1 8 .1 sometimes fail to assert m yself as much as I should. sd d n a sa
1 9 .1 seldom feel self-conscious when I’m around people. sd d n a sa
20. W hen I do things, I do them vigorously. sd d n a sa
2 1 .1 have trouble resisting my cravings. sd d n a sa
2 2 .1 w ouldn’t enjoy vacationing in Las Vegas. sd d n a sa
2 3 .1 feel I am capable o f coping with most o f my 
problems.
sd d n a sa
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2 4 .1 have sometimes experiences unique joy or ecstasy. sd d n a sa
2 5 .1 rarely feel fearful or anxious. sd d n a sa
26. I’m known as a warm and friendly person. sd d n a sa
2 7 .1 am known as hot blooded and quick tempered. sd d n a sa
SD = strongly disagree, D = disagree, N = neutra , A = agree. SA = strongly agree
2 8 .1 usually prefer to do things alone. sd d n a sa
2 9 .1 am seldom sad or depressed. sd d n a sa
3 0 .1 have often been a leader o f groups I have belonged 
to.
sd d n a sa
31. At times, I have been so ashamed, I just wanted to 
hide.
sd d n a sa
32. My work is likely to be slow but steady. sd d n a sa
3 3 .1 have little difficulty resisting temptation. sd d n a sa
3 4 .1 have sometimes done things just for “kicks” or 
“thrills.”
sd d n a sa
35. When I’m under a great deal o f stress, sometimes I 
feel like I ’m going to pieces.
sd d n a sa
3 6 .1 am not a cheerful optimist. sd d n a sa
3 7 .1 often feel tense and jittery. sd d n a sa
38. Many people think o f me as somewhat cold and 
distant.
sd d n a sa
3 9 .1 am not considered a touchy or temperamental 
person.
sd d n a sa
4 0 .1 really feel the need for other people i f f  am by 
myself for long.
sd d n a sa
4 1 .1 have sometimes experiences a deep sense o f guilt o f 
sinfulness.
sd d n a sa
42. In meetings, I usually let the others do the talking. sd d n a sa
43. It doesn’t embarrass me too much if  people ridicule 
and tease me.
sd d n a sa
4 4 .1 often feel as if  I’m bursting with energy. sd d n a sa
45. W hen I am having my favourite foods, I tend to eat 
too much.
sd d n a sa
4 6 .1 tend to avoid movies that are shocking or scary. sd d n a sa
4 7 .1 keep a cool head in emergencies. sd d n a sa
48. Sometimes I bubhle with happiness. sd d n a sa
49. I ’m seldom apprehensive about the future. sd d n a sa
5 0 .1 really enjoy talking to people. sd d n a sa
51.1 often get disgusted with people I have deal with. sd d n a sa
5 2 .1 prefer jobs that let me work alone without being 
bothered hy other people.
sd d n a sa
5 3 .1 tend to blame m yself when anything goes wrong. sd d n a sa
54. Other people often look to me to make decisions. sd d n a sa
5 5 .1 often feel inferior to others. sd d n a sa
56. I ’m  not as quick and lively as other people. sd d n a sa
5 7 .1 seldom give into m y impulses. sd d n a sa
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5 8 .1 like to be where the action is. sd d n a sa
59. It’s often hard for me to make up m y mind. sd d n a sa
6 0 .1 don’t consider m yself especially “light hearted.” sd d n a sa
6 1 .1 often worry about things that might go wrong. sd d n a sa
6 2 .1 find it easy to smile and be outgoing with strangers. sd d n a sa
63. It takes a lot to get me mad. sd d n a sa
64. I ’d rather vacation at a popular beach than at an sd d n a sa
isolated cabin in the woods.
65. I have a low opinion o f myself. sd d n a sa
6 6 .1 would rather go m y own way than be a leader o f sd d n a sa
others.
6 7 .1 feel comfortable in the presence o f  m y bosses or sd d n a sa
other authorities.
68.1 usually seem to be in a hurry. sd d n a sa
6 9 .1 sometimes eat m yself sick. sd d n a sa
7 0 .1 love the excitement o f roller coasters. sd d n a sa
71.1 can handle m yself pretty well in a crisis. sd d n a sa
7 2 .1 am a cheerful, high-spirited person. sd d n a sa
7 3 .1 have fewer fears than most people. sd d n a sa
7 4 .1 have strong emotional attachments to m y friends. sd d n a sa
75. At times I have felt bitter and resentful. sd d n a sa
76. Social gatherings are usually boring to me. sd d n a sa
77. Sometimes things look pretty bleak and hopeless to 
me.
sd d n a sa
78. In conversations, I tend to do most o f  the talking. sd d n a sa
79. If  I have said or done the wrong thing to someone, I Sd d n a sa
can hardly bear to face them again.
SD = strongly disagree, D = disagree, N = neutra , A = agree, SA = strongly agree
80. My life is fast paced. sd d n a sa
81. Sometimes I do things on impulse I later forget. sd d n a sa
8 2 .1 am attracted to bright colours and flashy styles. sd d n a sa
83. W hen everything seems to be going wrong, I can still 
make good decisions.
sd d n a sa
8 4 .1 rarely use words like “fantastic!” or “sensational!” to 
describe my experiences.
sd d n a sa
85. Frightening thoughts sometimes come into my head. sd d n a sa
8 6 .1 take a personal interest in people I work with. sd d n a sa
87. Even minor annoyances can be frustrating to me. sd d n a sa
8 8 .1 enjoy parties with lots o f people. sd d n a sa
89. Too often, when things go wrong, I get discouraged 
and feel like giving up.
sd d n a sa
9 0 .1 don’t find it easy to take charge o f  a situation. sd d n a sa
91. W hen people I know do foolish things, I get 
embarrassed for them.
sd d n a sa
9 2 .1 am a very active person. sd d n a sa
9 3 .1 am always able to keep m y feelings under control. sd d n a sa
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9 4 .1 like being part o f a crowd at sporting events. sd d n a sa
95. I’m pretty stable emotionally. sd d n a sa
9 6 .1 laugh easily. sd d n a sa
c) Below is a list of problems that people sometimes have. Please read each one carefully, and 
check the box that best describes HOW  MUCH THAT PROBLEM  HAS DISTRESSED 
OR BOTHERED YOU DURING THE PAST 7 DAYS INCLUDING TODAY.
not at all a ittle bit m oderately quite a bit extremely
Loss o f sexual interest or pleasure 
Feeling low in energy or slowed down 
Thoughts of ending your life 
Crying easily
Feelings o f heing trapped or caught 
Blaming yourself for things 
Feeling lonely 
Feeling blue
W orrying too much about things 
Feeling no interest in things 
Feeling hopeless about the future 
Feeling everything is an effort 
Feelings o f worthlessness
29. Reproductive Questions:
I) a) Have you ever been pregnant? (Only say YES if  you were 100% sure) 
YES NO
b) If yes, how m any times have you been pregnant? ________
c) How many children have you given birth to? _________
d) How many times have you miscarried? _________
e) How many times have you had an abortion? _________
f) Are you currently pregnant? (Circle your answer)
YES NO MAYBE
g) Some women report experiencing an increase in negative mood, irritability, or 
weepiness in the week or days prior to starting their period each month (during the
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premenstrual phase). To what extent do you experience such negative m ood changes prior to 
your period? (Circle your answer)
1 2 3 4 5
not at all a little moderately quite a bit extremely
2) a) Have you ever taken oral contraceptives? (Circle your answer) YES NO
b) If  you have ever taken oral contraceptives, look at the following side effects that 
some people might experience when taking oral contraceptives. Put a check heside any 
and all of the following side effects that you experienced when taking oral 
contraceptives. Please indicate what oral contraceptive brand you were taking when 
you experienced the side effect. Check all that apply, (see question 3 f  on p. 11 for a list 
o f some oral contraceptive brands)
Nausea/Vomi tin g ;_________
Breast size increase________
Decreased ability to orgasm _
Weight ga in_____________
Increased sex drive/arousal _
Fewer menstrual cram ps____
Positive Mood change______
Tiredness/fatigue__________
High blood p ressu re________
Irregular heartbeat_________
Clearer com plexion________
Complete loss o f periods___
Heavier periods (T bleeding)
Desire to become pregnant__




Increased ability to orgasm 
W eight lo s s_____________
Decreased sex drive/arousal
More menstrual cram ps____
Negative m ood change____
Dizziness/F aintness
Painful or tender b reasts_________
Swelling o f  breast or abdom en___
Complexion Problems (e.g., acne)
Sexual relationship en d ed ________
Lighter periods ( i  b leed ing)_____
Concerned about horm ones_____
Medical condition (Specify: )
Conflicts with another m edication_____________
Breakthrough bleeding (bleeding between periods)
c) At what age did you start using oral contraceptives? _years
d) If  you have ever taken oral contraceptives, complete the following:
I believe that oral contraceptives have affected m y mood (Circle the best answer)
Very Negatively 
0





e) I f  you believe that you have ever experienced a change in your mood when taking  
oral contraceptives, check any o f the following changes that you noticed in 
yourself:
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Check any o f those that apply:
 Slept more than usual  M ore jealous ____M ore moody
 Slept less than usual  Less jealous ____Less moody
 Depression_________________Sadness ____Lower self-esteem
 More pessimistic_______ ____M ore optimistic ____Higher self-esteem
 M ore irritable ____Less irritable ____Cried more than usual
 Feelings o f inferiority  M ore sensitive to criticism___Cried less than usual
 Disrupted sleep_____________Less sensitive to criticism ___ More self-critical
 More content/happy  Less trust in partner (fidelity) Less self-critical
 M ore Aggressive_______ ____M ore trust in partner (fidelity)  Less Aggression
f) Have negative mood side effects ever influenced you to stop taking oral 
contraceptives? (Circle best answer)
Yes No Somewhat
g) I f  you have ever discontinued oral contraceptives due to mood side effects, 
approximately how many days or months did you experienced these negative mood 
side effects before discontinuing use?
_________months and ________ days
h) I f  you have ever experienced negative mood side effects when taking oral 
contraceptives, what
was/were the name o f the oral contraceptive(s) that you were taking when you 
experienced these effects? (see list on next page (3g) if  you need help remembering 
the different types)
3) a) Are you currently taking oral contraceptives? (Circle your answer)
YES INO
b) I f  you are currently taking oral contraceptives, for how many years and m onths have 
you been taking your current oral contraceptive? years and________ m onths
c) How long in total have you taken any oral contraceptive? years and
months
d) W hy did you start taking oral contraceptives? (Check all that apply)
[ ] Birth Control [ ] Treat acne
[ ] For cycle regularity [ ] Other: ______________________
[ ] Due to a hormonal medical condition (Specify): __________________
[ ] I was taking another medication that could have produced birth defects
e) W hy are you currently taking oral contraceptives? (Check all that apply)
[ ] Birth Control [ ] Treat acne
[ ] For cycle regularity [ ] Other:______________________
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[ ] Due to a hormonal medical condition (Specify); __________________
[ ] I am currently taking another medication that could produce birth defects
f) If you are currently taking oral contraceptives, please put an X beside the type o f 
oral contraceptive you are currently taking.
Alesse Ortho-Cept
Brevicon 0.5/35 Ortho 7/7/7












4) a) How m any different types/brands o f  oral contraceptive have you taken? 
types/brands
b) Please list all o f  the different types o f oral contraceptives have you used? (Please list 
all. Refer to above list in 3f.)
c) If you have previously taken oral contraceptives but are not taking them  right now, 
how many years and months has it been since you last took oral contraceptives? 
years and months
d) If you ever stopped a type o f  oral contraceptive, why did you stop taking that oral 
contraceptive? Check the boxes for all that apply and indicate the oral contraceptive 
brand that you stopped taking due to the side effect (list continued on next page).
] Nausea/Vomiting:
1 Breast size increase
] Decreased ability to orgasm
] W eight g a in _____________
] Increased sex drive/arousal _
] H eadaches:_______
] Breast size decrease
] Increased ability to orgasm _
] W eight lo s s_____________
] Decreased sex drive/arousal




High blood p ressu re____
Irregular heartbeat_____
Clearer com plexion________
Complete loss o f periods___
Heavier periods ( t  bleeding)
Desire to become p regnan t_
Too hard to u s e ____________
Too expensive_____________
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_  [ ] More menstrual cram ps________
[ ] Negative mood change_________
[ ] Dizziness/F aintness_____________
[ ] Painful or tender b reasts_________
[ ] Swelling o f breast or abdom en___
[ ] Complexion Problems (e.g., acne)
_ [  ] Sexual relationship en d ed _______
 [ ] Lighter periods (4 bleeding) _
 [ ] Concerned about horm ones___
[ ] Medical condition (Specify: )
Conflicts with another m edication_____________
Breakthrough bleeding (bleeding between periods)
Physician recommended discontinuation_________
Other:
e) Do you have a biological m other or sister who has experienced negative mood 
effects while taking oral contraceptives? (Circle answer):
YES NO UNSURE
f) Have you ever taken a contraceptive that contained hormones but that was not oral 
contraceptives (e.g., contraceptive patch, vaginal ring, DepoProvera, hormonal 
implants, etc.)? (circle answer)
YES NO UNSURE
5) a) W hat is the average length o f  your menstrual cycle right now (i.e.. How m any days 
are there from the first day o f one period to the first day o f your next period -  most 
people range between 25 and 3 5 )? ______________ days
b) W hat is your average length o f  menstruation/bleeding when you are not taking  
oral contraceptives? (i.e., how many days does your period last? M ost people’s 
periods last between 1 and 10 days.) _____________ days
c) W hich statement best describes your menstrual cycle when you are not taking oral 
contraceptives? (Check the box with an “X” beside the appropriate response.)
[ ] I never have m y period.
[ ] Some months I get m y period and some months I don’t.
[ ] I usually get m y period every month, but it is irregular and I cannot predict 
when it will start.
[ ] I usually get m y period within two or three days o f when I expect it.
[ ] My period is like clockwork and the same number o f days elapse between 
periods each month.
d) How old were you when you first started menstruating (started your period)? 
years old
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e) As a teenager and young adult, how did/does you acne/pimples compare to your
same-age peers? I h a d ____________ acne compared to most girls/women my age
(circle the best response).
S ig n if ica n tly  L ess  S lig h tly  L e ss  A b o u t th e  sam e S lig h tly  M o re  S ig n if ica n tly  M o re
0 1 3 4 5
6) a) Have you ever purposely tried to lose weight?
YES NO M AYBE
b) If  yes, at what age did you first attempt to lose weight? ________ years
c) At the current time, are you purposely trying to lose weight? (circle your answer)
YES NO MAYBE
d) During the past five years, how m uch o f the time have you been purposely trying to 
lose weight?(circle your answer)
Virtually Almost all
never o f the time
1 2 3 4 5 6 7 8 9
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Appendix B
CONSENT FORM A
This study is being conducted by  Dr. Kirsten Oinonen o f the Department o f  Psychology 
at Lakehead University. Portions o f  this project will be used as M aster’s theses for Ms. Jessica 
Bird, and Ms. Meghan Richards. The purpose o f the study is to examine genetic factors in 
w om en’s health. You will receive one bonus point towards your Introductory Psychology mark 
for completing this screening questionnaire. The questionnaire will be used to select subjects for 
one o f two studies. Individuals who participate in the subsequent studies will receive an 
additional one or two bonus points (depending on which study they are selected for) towards 
their final mark in Introductory Psychology. Please complete the attached bonus point form if  
you are in Introductory Psychology to ensure that you receive the bonus point.
Your participation in the screening will involve the completion o f  a questionnaire that 
will take approximately 40 minutes. The questionnaire includes personal questions about topics 
such as; demographic information, health information, medical information, reproductive 
history, relationship information, personalities and mood.
Participation in this experiment is voluntary and you may withdraw at any time without 
explanation and without penalty. All records o f your participation will be kept in strict 
confidence and any reports o f  the study will not identify you as a participant. As per university 
requirements, all data will be stored for seven years by Dr. K. Oinonen at Lakehead University 
and remain anonymous and confidential. Individuals who meet specific criteria will be asked to 
participate in the studies. Therefore, w e have asked for your name and telephone number on this 
form (please do not detach the form). Once we have determined who will be asked to participate 
in the next phase, this sheet will be removed from your questionnaire and your information will 
remain both anonymous and confidential. There will be no way that your name can be 
connected to your responses. There are no known physical or psychological risks associated 
with participating in this study. If you have any questions or concerns regarding this study 
please contact Dr. Kirsten Oinonen (343-8096).
I have read and understood the consent form, and I agree to participate in this study under 
these conditions.
Name (Please P rin t);_____________________________  Phone Number:
Signature: _________________________________________  D a te :______
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Appendix C 
DEBRIEFING FORM  A 
Thank you for participating in the screening phase o f  our study. The study is being 
conducted by Dr. Oinonen, Ms. Richards, and Ms. Bird. Portions o f  this research constitute 
M aster’s theses by Ms. Richards and Ms. Bird. I f  you are selected to participate in the second 
part o f the study, you will be contacted by one of the researchers in the next three weeks. 
Participants in the next phases o f the study will receive either one or two additional points 
towards their final m ark (if  they are Psychology 1100 students). I f  you are chosen for one o f  the 
next phases, you will be asked to provide a DNA sample (oral swab) and complete additional 
questionnaires.
Please be assured that once participants have been selected for the study, the consent
forms will be removed from  the questiormaires and there will be no way to identify your
responses. All o f your responses will be coded to conceal your identity on the questionnaires
and all data will remain anonymous. I f  you have any questions, please feel free to contact Dr.
Oinonen at the contact information below.
Kirsten Oinonen, Ph.D. C. Psych.
Department o f  Psychology
Lakehead University
955 Oliver Road
Thunder Bay, ON P7B 5E1
(807) 343-8086, koinonen@ lakeheadu.ca
Ms. Jessica Bird, MA Candidate
Department o f  Psychology
Lakehead University
955 Oliver Road
Thunder Bay, ON P7B 5E1
jbird@ lakeheadu.ca
Ms. Meghan Richards, MA Candidate
Department o f  Psychology
Lakehead University
955 Oliver Road
Thunder Bay, ON P7B 5E1
mri char4@ lakeheadu. ca
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Appendix D
CONSENT FORM B
I agree to participate in this study that is investigating genetic factors in w om en’s health. I 
understand that m y participation is entirely voluntary: I can leave the experiment at any time and 
this will have no bearing on any remuneration I will receive, nor will it have any undesirable 
consequences.
The following points have been explained to me:
1. The purpose o f this research is to find out what factors are related to w om en’s health.
The benefits I m ay expect from the study are (a) an appreciation o f research on health, (b) 
an opportunity to contribute to scientific research and (c) course credit (One bonus point 
for Introductory Psychology Students).
2. The procedure will be as follows: During a single session, researchers will obtain a DNA 
sample (via an oral swab) and m y body measurements (e.g. height, weight, hand 
measurements) will be taken, I will then be required to complete a total o f  three paper 
and pencil questionnaires.
3. There are no known serious risks involved in participating in this study.
4. All o f the data collected as well as my DNA sample will remain strictly confidential. My 
responses will not be associated with my name. Instead, my data will be associated with a 
code number when the researchers store the data.
5. The experimenter(s) will answer any other questions about the research either now or 
during the course o f  the experiment (other than specific questions about the hypotheses). 
If  I have any other questions or concerns, I can address them to the experimenter(s) 
M eghan Richards (mrichar4@lakeheadu.ca) or Jessica Bird (jbird(@lakeheadu.ca) or to 
the research director. Dr. Kirsten Oinonen 343-8096, (koinonen@ lakeheadu.ca).
6. Upon completion o f my participation, I will receive a more detailed written explanation 
about the rationale underlying this experiment.
7. I am interested in receiving a summary o f the results upon completion o f  the study:
yes □  no □
If yes, please indicate your email address:_______________________________
Participant’s Printed Name Signature
Date Experimenter Name
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Appendix E
DEBRIEFING FORM  B
Principal Investigators! Dr. K. Oinonen, Psychology Department,
Lakehead University,
955 Oliver Road 
n runder Bay, ON P7E 5E1 
koinonen@ lakeheadu.ca, 343-8096
Ms. Meghan Richards, MA Candidate,
Psychology Department 
Lakehead University
955 Oliver Road, Thunder Bay, ON P7E 5E1 
mrichar4@ lakeheadu.ca
Ms. Jessica Bird, MA Candidate,
Psychology Department 
Lakehead University
955 Olivei' Road, Thunder Bay, ON P7E 5E1 
jbird@ lakeheadu.ca
We appreciate your participation in our study, and thank you for spending your time to help us with our 
research. W hen you arrived here you were told that the purpose o f  this study w as to investigate genetic ioctors 
relating to w om en’s health. One o f  the factors in  which we are interested is how  genetic factors are related to m ood 
in young women. In order to examine mood, we attempted to induce a negative m ood state by telling you that we 
w ould be evaluating your intelligence based on your perform ance on a mental rotation test. W e want to assure you 
that this test is not a m easure o f  your intellectual ability.
W e m isled you about this test because we expected that people may have responded differently if  they had 
known the nature o f  our research questions. W e apologize, and hope you understand w hy it was necessary. As you 
can see, we would not have been  able to investigate this research question w ithout misleading you regarding the 
exact purpose o f  the test. In case you have any concerns about your mood and w ould like to see a mental health 
professional, we have provided you with a list o f  such resources on the attached sheet.
G iven that this study involves some aspects o f  which you were not fully inform ed at the start, it is very 
im portant that you not discuss your experiences w ith other smdents until the end o f  the term. I f  participants have 
p rio r knowledge o f  our specific predictions it w ould influence their results, and the data we collect would be not be 
useable. Since you will be given a copy o f  this feedback to take home, please do not make it available to other 
students. If  you do not keep this form, please dispose o f  it rather than leaving it som ewhere that other sm dents m ight 
read it.
Please feel free to discuss w ith the experim enter any feelings you have about the smdy right away. Should 
you have further questions, do not hesitate to contact Meghan Richards, Jessica Bird, or Dr. K irsten Oinonen, using 
the inform ation listed above.
W e hope that you have enjoyed participating in our smdy, and thank you very m uch for your assistance. As 
noted on the consent form, you will receive a sum m ary o f  the results o f  the smdy at its com pletion if  you have 
indicated an interest. Please see the reverse o f  this page for a list o f  mental health resources and journal articles 
relevant to this research.
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Appendix E continued
M ental H ealth Resource Sheet
Som etim es people can feel upset when thinking about their mood. I f  you feel as though you would like to talk to a 
m ental health practitioner for any reason please consider the resources listed below:
•  Lakehead University H ealth and Counseling Centre: 343-8361
•  Fam ily Services Thunder Bay: 626-1880
• Catholic Fam ily D evelopm ent Centre: 345-7323
• Em ergency services are available at the Thunder Bay Health Sciences Centre
•  Thunder B ay Crisis R esponse (24 hours): 346-8282.
I f  you are interested in doing further reading that is related to this study, here are three relevant journal articles that 
you m ight want to obtain.
Ogilvie, A.D., Battersby, S., Bubb, V. J., Fink, G., Harmar, A. J., Goodwin, G. M., & Smith, C.A.D.
(1996). Polym orphism  in serotonin transporter gene associated with susceptibility to major depression. 
Lancet, 347, 731-733.
Oinonen, K., & M azmanian, D. (2002). To w hat extent do oral contraceptives influence mood and affect?
Journal o f  Affective Disorders, 70, 229-240.
W ade, T.D., W ilkinson, J., & Ben-Tovim, D. (2003). The genetic epidem iology o f  body attitudes, the 
attimdinal com ponent o fb o d y  image in women. Psychological Medicine 33, 1395-1405.
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Appendix F
CONSENT FORM C
The study that you have just participated in is being conducted by Dr. Kirsten Oinonen o f the 
Department o f  Psychology at Lakehead University, and graduate students Ms. Jessica Bird, and 
Ms. Meghan Richards. The purpose o f the study is to examine genetic factors in women’s health. 
Given the valuable time and data that you have contributed to this study, w e hope to maximally 
contribute to scientific knowledge with this data. If  our hypotheses are supported in the current 
study and/or if  there appears to be value in conducting a longitudinal follow-up project, we 
would like to ask for your permission to contact you within the next five years, to ask whether 
you might be willing to participate in a follow-up study. Any follow-up study would only be 
conducted if  it had received ethical clearance by the Lakehead University Research Ethics Board 
and any relevant granting agency. Thus, you can be assured that you would only be contacted in 
such a situation. Furthermore, your signature on this form does not constitute your consent to 
participate in a follow-up study. Your signature on this form would only allow us the opportunity 
to attempt to contact you to see if  you are interested in participating. I f  we were to receive ethics 
approval for such a study, we would open up the sealed envelope that you would be sealing 
today. This envelope will contain your name, participant number, and contact information (e- 
mail addresses, telephone numbers, addresses). The envelope would only be opened in such a 
situation, and will be destroyed if  a follow-up study is not planned within the next five years.
Participation in this portion o f the study is voluntary and you m ay withdraw at any time 
without explanation and without penalty. All records o f your participation will be kept in strict 
confidence and any reports o f  the study will not identify you as a participant. As per university 
requirements, all data will be stored for seven years by Dr. K. Oinonen at Lakehead University 
and remain anonymous and confidential. There are no known physical or psychological risks 
associated with participating in this study. I f  you have any questions or concerns regarding this 
study please contact Dr. Kirsten Oinonen (343-8096).
I have read and understood the consent form, and I agree to participate in this study under 
these conditions.
Name (Please Print):
Signature: __________________________________________  Date:
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Appendix G
Categorization o f Participant-Listed Ethnicities by W orld Region
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Appendix H
Intercorrelations Between ED I-II Items and Num ber o f  OC M ood and Physical Side Effects
EDI-II Item Coirelation with 
Number o f OC 
Mood Side Effects
Correlation with 
Number o f  OC 
Physical Side Effects
I eat sweets and carbohydrates w ithout feeling nervous 
(DT)
-T35 ^203**
1 think my thighs are just the right size (BD) -.226** -.149
1 think that my hips are ju st the right size (BD) -.119 -.164*
1 feel satisfied with the shape o f  m y body (BD) -T39 -T57*
1 think about dieting (DT) T94* .270**
1 think that my thighs are too large (BD) 225** ^01**
1 feel extrem ely guilty after overeating (DT) .216** .236**
1 am terrified o f gaining w eight (DT) .147 .273**
1 exaggerate or magnify the im portance o f  weight (DT) T93* T52*
1 am preoccupied with the desire to be thinner (DT) T36 ^26**
1 think about bingeing (overeating) (BU) .097 T54*
1 think my hips are too big (BD) .149 ^41**
I f f  gain a pound, 1 worry that 1 will keep gaining (DT) T95* .264**
1 have the thought o f  trying to vom it in order to lose 
w eight (BU)
T95* T85*
1 think m y buttocks are too large (BD) T91* .249**
Note. DT = Drive for Thinness subscales; BD 
subscale.
* p  < .05. ** p  < .01.
Body Dissatisfaction subscale; BU = Bulim ia
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Appendix I
Spearman Correlations Between OC Side Effects, Body Dissatisfaction and Eating Dysfunction
OC Side Effect Body Dissatisfaction Score Eating Dysfunction Score
W eight gain .191* 295* *
Breast size increase .008 .048
Swelling o f  the abdomen ^004 .001
Depression T76* T90*
More irritability ^69** J#2**
Headache .252** H64*
*  p  < .05. ** p  < .01.
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Appendix J
Intercorrelations fo r  Eating Disorder Symptoms, OC Side Effects, and Other Variables
M easure BD EDy MSB FSE BM l Dep Neur
13D -  .703** .216** ^14** .431** .421** A94**
EDy .244** .276** .311** 507* * ^89**
MSB — 447** -.017 .340** 214**
FSE — T28 274** T59
BM l — T38* T53*
Dep — 222**
Neur —
Note. BD = body dissatisfaction score; EDy = eating dysfunction score; MSB = number o f  oral 
contraceptive mood side effects; PSE = number o f oral contraceptive physical side effects; BM l 
= body mass index; Dep = current depression score; Neur = neuroticism score. Sample sizes 
range from 138 to 260.
**. p <  . Q \ , * . p <  .05.
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